<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US7604929 - Hepatocyte cryopreservation; density gradient fractionation/centrifugation ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Hepatocyte cryopreservation; density gradient fractionation/centrifugation through polyvinylpyrrolidone-coated colloidal silica particles"><meta name="DC.contributor" content="Daniel Dryden" scheme="inventor"><meta name="DC.contributor" content="James Hardy" scheme="inventor"><meta name="DC.contributor" content="In Vitro Technologies, Inc." scheme="assignee"><meta name="DC.date" content="2005-4-21" scheme="dateSubmitted"><meta name="DC.description" content="The present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed."><meta name="DC.date" content="2009-10-20" scheme="issued"><meta name="DC.relation" content="EP:0834252" scheme="references"><meta name="DC.relation" content="US:20020039786:A1" scheme="references"><meta name="DC.relation" content="US:20030134418:A1" scheme="references"><meta name="DC.relation" content="US:5795711" scheme="references"><meta name="DC.relation" content="US:5895745" scheme="references"><meta name="DC.relation" content="US:6136525" scheme="references"><meta name="DC.relation" content="US:6759245" scheme="references"><meta name="DC.relation" content="WO:1992012722:A1" scheme="references"><meta name="DC.relation" content="WO:2001053462:A1" scheme="references"><meta name="DC.relation" content="WO:2003105663:A2" scheme="references"><meta name="DC.relation" content="WO:2004009766:A2" scheme="references"><meta name="DC.relation" content="WO:2005000376:A2" scheme="references"><meta name="citation_reference" content="Adams, R.M. et al. (1995) &quot;Effective Cryopreservation And Long-Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential,&quot; Cell Transplant. 4(6):579-586."><meta name="citation_reference" content="Alexandre, E. et al. (2002) &quot;Cryopreservation Of Adult Human Hepatocytes Obtained From Resected Liver Biopsies,&quot; Cryobiology 44:103-113."><meta name="citation_reference" content="Anand, A.C. (1996) &quot;Bioartificial Livers: The State Of The Art,&quot; Trop Gastroenterol. 17(4):197-198, 202-211."><meta name="citation_reference" content="Arikura et al., UW solution: a promising tool for cryopreservation of primarily isolated rat hepatocytes, 9 J. Hepatobiliary Pancreat. Surg. 742-749 (2002)."><meta name="citation_reference" content="Berry, M.N. et al. (1992) &quot;Techniques for Pharmacological And Toxicological Studies With Isolated Hepatocyte Suspensions,&quot; Life Sci. 51(1):1-16."><meta name="citation_reference" content="Burlina, A.B. (2004) &quot;Hepatocyte Transplantation For Inborn Errors Of Metabolism,&quot; J. Inherit. Metab. Dis. 27(3):373-83."><meta name="citation_reference" content="Chan, C. et al. (2004) &quot;Hepatic Tissue Engineering For Adjunct And Temporary Liver Support: Critical Technologies,&quot; Liver Transpl. 10(11):1331-1342."><meta name="citation_reference" content="Chesne, C. et al. (1993) &quot;Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation,&quot; Hepatology 18(2):406-414."><meta name="citation_reference" content="Coundouris, J.A. et al. (1993) &quot;Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies,&quot; Xenobiotica. 23(12):1399-1409."><meta name="citation_reference" content="Diener, B. et al. (1993) &quot;A Method For The Cryopreservation Of Liver Parenchymal Cells For Studies Of Xenobiotics,&quot; Cryobiology 30(2):116-127."><meta name="citation_reference" content="Dou, M. et al. (1992) &quot;Thawed Human Hepatocytes In Primary Culture,&quot; Cryobiology 29(4):454-69."><meta name="citation_reference" content="Fox, I.J. et al. (2004) &quot;Hepatocyte Transplantation,&quot; Am. J. Transplant.4 Suppl. 6:7-13."><meta name="citation_reference" content="Fukuda, J. et al. (2004) &quot;Hepatocyte Organoid Culture In Elliptic Hollow Fibers To Develop A Hybrid Artificial Liver,&quot; Int J Artif Organs. 27(12):1091-1099."><meta name="citation_reference" content="Gan, J.H. et al. (2005) &quot;Hybrid Artificial Liver Support System For Treatment of Severe Liver Failure,&quot; World J Gastroenterol. 11(6):890-894."><meta name="citation_reference" content="Gomez-Lechon, M.J. et al. (2004) &quot;Human Hepatocytes In Primary Culture: The Choice To Investigate Drug Metabolism in Man,&quot; Curr Drug Metab. 5(5):443-462."><meta name="citation_reference" content="Guillouzo, A. et al. (1986) &quot;Isolated and Cultured Hepatocytes,&quot; Paris: les Editions INSERM and London: John Libbey Eurotext)."><meta name="citation_reference" content="Hengstler et al., Drug Metab. Rev., 2000, 32: 81-118, Abstract."><meta name="citation_reference" content="Hewitt, N.J. et al. (2004) Cryopreserved Rat, Dog and Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures, Hum Exp Toxicol. 23(6)307-316."><meta name="citation_reference" content="Horslen, S.P. (2004) &quot;Hepatocyte Transplantation,&quot; Transplantation 77(10):1481-1486."><meta name="citation_reference" content="Houle, r. et al. (2003) &quot;Retention Of Transporter Activities in Cryopreserved, Isolated Rat Hepatocytes,&quot; Drug Metab. Disposit. 31(4):447-451."><meta name="citation_reference" content="Kasai, s. et al. (1993) &quot;Large Scale Cryopreservation of Isolated Dog Hepatocytes,&quot; Cryobiology 30:1-11."><meta name="citation_reference" content="Lawrence, J.N. et al. (1991) &quot;Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture. Toxicology In Vitro,&quot; 5(1):39-51."><meta name="citation_reference" content="Lee, S. W. et al. (2004) &quot;Hepatocyte Transplantation: State Of The Art And Strategies For Overcoming Existing Hurdles,&quot; Ann. Hepatol. 3(2):48-53."><meta name="citation_reference" content="Lemaigre, F. et al. (2004) &quot;Liver Development Update: New Embryo Models, Cell Lineage Control, And Morphogenesis,&quot; Curr Opin Genet Dev. 14(5):582-590."><meta name="citation_reference" content="Li et al., Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics . . . , 121 Chemico-Biological Interactions 117-123 (1999)."><meta name="citation_reference" content="Li, A.P. et al. (1992) &quot;Isolation And Culturing Of Hepatocytes From Human Liver,&quot; J. Tissue Cult. Meth. 14:139-146."><meta name="citation_reference" content="Li, A.P. et al. (1999) &quot;Cryopreserved Human Hepatocytes: Characterization Of Drug-Metabolizing Enzyme Activities And Applications In Higher Throughput Screening Assays For Hepatotoxicity, Metabolic Stability, And Drug-Drug Interaction Potential,&quot; Chem Biol Interact. 121(1):17-35."><meta name="citation_reference" content="Li, A.P. et al. (1999) &quot;Present Status Of The Application Of Cryopreserved Hepatocytes In The Evaluation Of Xenobiotics: Consensus Of An International Expert Panel,&quot; Chem Biol Interact. 121(I):117-123."><meta name="citation_reference" content="Li, Overview: hepatocytes and cryopreservation-a personal historical perspective, 121 Chemico-Biological Interactions 1-5 (1999)."><meta name="citation_reference" content="Lloyd, T.D.R. et al. (2003) Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking, Cell and Tissue Culture Banking 4:3-15."><meta name="citation_reference" content="Loretz, L.J. et al. (1989) &quot;Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes,&quot; Xenobiotica. 19(5):489-498."><meta name="citation_reference" content="Madan, A. et al. (1999)&quot;Effect of Cryopreservation on Cytochrome P-450 Enzyme Induction in Cultured Rat Hepatocytes,&quot; Drug Metab. Dispos. 27(3):327-335."><meta name="citation_reference" content="Marsh et al., Hypothermic Preservation of Hepatocytes III Effects of Resuspension Media on Viability after up to 7 Days of Storage, 13(3) Hepatology 500-508 (1991)."><meta name="citation_reference" content="Meng, Q. et al. (2004) &quot;Hepatocyte Culture In Bioartificial Livers With Different Membrane Characteristics,&quot; Biotechnol Lett. 26(18):1407-1412."><meta name="citation_reference" content="Morsiani et al., (1995) &quot;Automated Liver Cell Processing Facilitates Large Scale Isolation And Purification Of Porcine Hepatocytes,&quot; ASAIO Journal 41:155-161."><meta name="citation_reference" content="Nanji, A.A. (2004) &quot;Animal Models Of Nonalcoholic Fatty Liver Disease And Steatohepatitis,&quot; Clin Liver Dis. 8(3):559-574."><meta name="citation_reference" content="Novicki, D.L. et al. (1982) &quot;Cryopreservation Of Isolated Rat Hepatocytes,&quot; In Vitro. 18(4):393-399."><meta name="citation_reference" content="O&#39;Brien, Z.Z. et al. (undated) &quot;The Construction Of A Representative Human Cryopreserved Hepatocyte Pool For Metabolism Study,&quot;."><meta name="citation_reference" content="Oehninger et al., Mol Cell Endocrinol, 2000, 169: 3-10."><meta name="citation_reference" content="Ostrowska et al., Cell and Tissue Banking, 2000, 1: 55-68."><meta name="citation_reference" content="Ponsoda, X. et al. (2004) &quot;Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?&quot; Altern Lab Anim. 32(2): 101-110."><meta name="citation_reference" content="Postic, C. et al. (2004) &quot;Role Of The Liver In The Control Of Carbohydrate And Lipid Homeostasis,&quot; Diabetes Metab. 30(5):398-408."><meta name="citation_reference" content="Roymans, D. et al. (2004) &quot;Determination Of Cytochrome P450 1A2 And Cytochrome P4503a4 Induction In Cryopreserved Human Hepatocytes,&quot; Biochem Pharmacol. 67(3):427-437."><meta name="citation_reference" content="Ruegg, C.E. et al. (1997) &quot;Cytochrome-P450 Induction and Conjugated Metabolism In Primary Human Hepastocytes After Cryopreservation,&quot; In Vitro Toxicol. 10:217-222."><meta name="citation_reference" content="Seglen, P.O. (1976) &quot;Preparation Of Isolated Rat Liver Cells,&quot; Meth. Cell Biol. 13:29-83)."><meta name="citation_reference" content="Sekido, H. el al. (2004) &quot;Usefulness Of Artificial Liver Support For Pretransplant Patients With Fulminant Hepatic Failure,&quot; Transplant Proc. 36(8):2355-2356."><meta name="citation_reference" content="Shaddock, J,G. et al. (1993) &quot;Cryopreservation And Long-Term Storage Of Primary Rat Hepatocytes: Effects On Substrate-Specific Cytochrome P450-Dependent Activities And Unscheduled DNA Synthesis,&quot; Cell Biol Toxicol. 9(4):345-357."><meta name="citation_reference" content="Shibata et al., Drug Metabolism and Disposition, 2002, 30: 892-896."><meta name="citation_reference" content="Silva, J.M. et al. (1999) &quot;Induction Of Cytochrome-P450 In Cryopreserved Rat And Human Hepatocytes,&quot; Chem-Biol Interact 121:49-63."><meta name="citation_reference" content="Smrzova et al., Optimisation of Porcine Hepatocyte Cryopreservation by Comparison of Viability and Enzymatic Activity of Fresh and Cryopreserved Cells, 70 Acta Vet. Bmo. 141-147 (2001)."><meta name="citation_reference" content="Sun, E.L. et al. (1990) &quot;Cryopreservation Of Cynomologus Monkey (Macaca fascicularis) Hepatocytes For Subsequent Culture And Protein Synthesis Studies,&quot; In vitro Cell Development and Biology 25:147-150."><meta name="citation_reference" content="Utesch, D. et al. (1992) &quot;Characterization Of Cryopreserved Rat Liver Parenchymal Cells By Metabolism Of Diagnostic Substrates And Activities Of Related Enzymes,&quot; Biochemical Pharmacology 44:309-315."><meta name="citation_reference" content="Vincent et al., Adjustment of the Osmolality of Percoll for the Isopycnic Separation of Cells and Cell Organelles, 141 Analytical Biochemistry 322-328 (1984)."><meta name="citation_reference" content="Zaleski, J. et al. (1993) &quot;Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen,&quot; Biochem Pharmacol. 46(1):111-116."><meta name="citation_reference" content="Zhang, J.G. et al. (undated) &quot;Validation of Pooled Cryopreserved Human Hepatocytes as a Model for Metabolism Studies&quot; www. Bdbiosciences.com."><meta name="citation_patent_number" content="US:7604929"><meta name="citation_patent_application_number" content="US:11/110,879"><link rel="canonical" href="http://www.google.com/patents/US7604929"/><meta property="og:url" content="http://www.google.com/patents/US7604929"/><meta name="title" content="Patent US7604929 - Hepatocyte cryopreservation; density gradient fractionation/centrifugation through polyvinylpyrrolidone-coated colloidal silica particles"/><meta name="description" content="The present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed."/><meta property="og:title" content="Patent US7604929 - Hepatocyte cryopreservation; density gradient fractionation/centrifugation through polyvinylpyrrolidone-coated colloidal silica particles"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("JVfsU7DJAuunsATggIHgAg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("USA"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("JVfsU7DJAuunsATggIHgAg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("USA"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us7604929?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US7604929"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=-FvnBQABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS7604929&amp;usg=AFQjCNG32JrVwUGtmKzwYapRnSpe6x9R4A" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US7604929.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US7604929.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20050239042"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US7604929"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US7604929" style="display:none"><span itemprop="description">The present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability....</span><span itemprop="url">http://www.google.com/patents/US7604929?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US7604929 - Hepatocyte cryopreservation; density gradient fractionation/centrifugation through polyvinylpyrrolidone-coated colloidal silica particles</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US7604929 - Hepatocyte cryopreservation; density gradient fractionation/centrifugation through polyvinylpyrrolidone-coated colloidal silica particles" title="Patent US7604929 - Hepatocyte cryopreservation; density gradient fractionation/centrifugation through polyvinylpyrrolidone-coated colloidal silica particles"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US7604929 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 11/110,879</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Oct 20, 2009</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Apr 21, 2005</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Apr 21, 2005</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2604693A1">CA2604693A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2604693C">CA2604693C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN101501186A">CN101501186A</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN101501186B">CN101501186B</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN103275924A">CN103275924A</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1891208A2">EP1891208A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1891208B1">EP1891208B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2218777A1">EP2218777A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2479259A2">EP2479259A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2479259A3">EP2479259A3</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20050239042">US20050239042</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20100075294">US20100075294</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20100075295">US20100075295</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2006115682A2">WO2006115682A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2006115682A3">WO2006115682A3</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">110879, </span><span class="patent-bibdata-value">11110879, </span><span class="patent-bibdata-value">US 7604929 B2, </span><span class="patent-bibdata-value">US 7604929B2, </span><span class="patent-bibdata-value">US-B2-7604929, </span><span class="patent-bibdata-value">US7604929 B2, </span><span class="patent-bibdata-value">US7604929B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Daniel+Dryden%22">Daniel Dryden</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22James+Hardy%22">James Hardy</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22In+Vitro+Technologies,+Inc.%22">In Vitro Technologies, Inc.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US7604929.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7604929.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7604929.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (12),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (55),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (4),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (11),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (18)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/7604929&usg=AFQjCNGCydjzMc9ie3d70agHJhQtQghjJA">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D7604929&usg=AFQjCNGyedlr6JyvUtdVZrEDdZzCsa3xXA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D7604929B2%26KC%3DB2%26FT%3DD&usg=AFQjCNGBYU6bhzYY_VBM1uIUisORbfElWQ">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT130072235" lang="EN" load-source="ifi">Hepatocyte cryopreservation; density gradient fractionation/centrifugation through polyvinylpyrrolidone-coated colloidal silica particles</invention-title></span><br><span class="patent-number">US 7604929 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA62686852" lang="EN" load-source="patent-office"> <div num="p-0001" class="abstract">The present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(15)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7604929-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7604929-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(11)</span></span></div><div class="patent-text"><div mxw-id="PCLM23159257" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-00001" num="00001" class="claim">
      <div class="claim-text">1. A method of producing a desired preparation of multi-cryopreserved hepatocytes, said hepatocytes, being capable of being frozen and thawed at least two times, and in which greater than 70% of the hepatocytes of said preparation are viable after the final thaw, said method comprising:
<div class="claim-text">(A) subjecting hepatocytes that have been frozen and thawed to density gradient fractionation to separate viable hepatocytes from non-viable hepatocytes,</div>
<div class="claim-text">(B) recovering the separated viable hepatocytes, and</div>
<div class="claim-text">(C) cryopreserving the recovered viable hepatocytes to thereby form said desired preparation of hepatocytes without requiring a density gradient step after thawing the hepatocytes for the second time, wherein the hepatocytes are not plated between the first and second cryopreservations, and wherein greater than 70% of the hepatocytes of said preparation are viable after the final thaw.</div>
</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00002" num="00002" class="claim">
      <div class="claim-text">2. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said density gradient fractionation comprises density centrifugation through polyvinylpyrrolidone-coated colloidal silica particles.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00003" num="00003" class="claim">
      <div class="claim-text">3. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00004" num="00004" class="claim">
      <div class="claim-text">4. The method of <claim-ref idref="CLM-00003">claim 3</claim-ref>, wherein said hepatocytes are human hepatocytes.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00005" num="00005" class="claim">
      <div class="claim-text">5. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said preparation comprises a pooled preparation of hepatocytes of multiple sources.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00006" num="00006" class="claim">
      <div class="claim-text">6. The method of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein said multiple sources are of the same gender, race, or health state.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00007" num="00007" class="claim">
      <div class="claim-text">7. The method of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the hepatocytes of said pooled preparation of hepatocytes provide said pooled preparation with a desired level of a metabolic activity.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00008" num="00008" class="claim">
      <div class="claim-text">8. The method of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein said metabolic activity is selected from the group consisting coumarin 7-hydroxylase (COUM), dextromethorphan O-demethylase (DEX), 7-ethoxycourmarin O-deethylase (ECOD), activities responsible for the phase II metabolism of 7-hydroxycoumarin (7-HCG and 7-HCS), mephenytoin 4-hydroxylase (MEPH), testosterone 6(β)-hydroxylase (TEST), tolbutamide 4-hydroxylase (TOLB), phenacetin O-deethylase (PHEN), and chloroxazone 6-hydroxylase (CZX).</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00009" num="00009" class="claim">
      <div class="claim-text">9. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein greater than 80% of the hepatocytes of said preparation are viable.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00010" num="00010" class="claim">
      <div class="claim-text">10. A method of investigating in vitro drug metabolism comprising incubating hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence of a xenobiotic, and determining the metabolic fate of the xenobiotic, or the affect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity thereof, wherein the hepatocytes have been frozen and thawed at least two times, and wherein greater than 70% of the hepatocytes of said preparation are viable without requiring a density gradient step after thawing the hepatocytes for the second time, wherein the hepatocytes are not plated between the first and second cryopreservations.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00011" num="00011" class="claim">
      <div class="claim-text">11. The method of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein said multiple sources are of different gender, race or health state.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES28137989" lang="EN" load-source="patent-office" class="description">
    <heading>FIELD OF THE INVENTION</heading> <p num="p-0002">The present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p num="p-0003">Hepatocytes are parenchymal liver cells, and make up 60-80% of the cytoplasmic mass of the liver. Hepatocytes play a key role in the detoxification, modification and excretion of exogenous and endogenous substances (Ponsoda, X. et al. (2004) “<i>Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?”</i> Altern Lab Anim. 32(2): 101-110). One of the detoxifying functions of hepatocytes is to modify ammonia to urea for excretion. They are also important in protein synthesis and storage, in the transformation of carbohydrates and in the synthesis of cholesterol, bile salts and phospholipids (Postic, C. et al. (2004) “<i>Role Of The Liver In The Control Of Carbohydrate And Lipid Homeostasis,” </i>Diabetes Metab. 30(5):398-408). The hepatocyte is the only cell in the body that manufactures albumin, fibrinogen, and the prothrombin group of clotting factors. It is the main site for the synthesis of lipoproteins, ceruloplasmin, transferrin, and glycoproteins. Hepatocytes manufactures their own structural proteins and intracellular enzymes. Hepatocytes are also important depots for vitamin B12 and iron.</p>
    <p num="p-0004">Due to these attributes, isolated and cultured hepatocytes have become very attractive as models systems for the study of liver functions (Chesne, C. et al. (1993) “<i>Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation,”</i> Hepatology 18(2):406-414; Guillouzo, A. et al. (1986) “<i>Isolated and Cultured Hepatocytes,” </i>Paris: les Editions INSERM and London: John Libbey Eurotext); Ponsoda, X. et al. (2004) “<i>Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?”</i> Altern Lab Anim. 32(2): 101-110; Gomez-Lechon, M. J. et. al. (2004) “<i>Human Hepatocytes In Primary Culture: The Choice To Investigate Drug Metabolism In Man,”</i> Curr Drug Metab. 5(5):443-462; Lemaigre, F. et al. (2004) “<i>Liver Development Update: New Embryo Models, Cell Lineage Control, And Morphogenesis,”</i> Curr Opin Genet Dev. 14(5):582-590; Nanji, A. A. (2004) “<i>Animal Models Of Nonalcoholic Fatty Liver Disease And Steatohepatitis,”</i> Clin Liver Dis. 8(3):559-574; Hewitt, N. J. et al. (2004) <i>Cryopreserved Rat, Dog And Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures,”</i> Hum Exp Toxicol. 23(6):307-316).</p>
    <p num="p-0005">In addition to their use in liver models, hepatocytes have the potential of being used to produce Bioartificial Livers (BALs) or in hepatocyte transplantation that can provide liver functions for individuals suffering from liver disease or liver failure. Bioartificial Livers (BALs) are described by Anand, A. C. (1996) <i>“Bioartificial Livers: The State Of The Art,”</i> Trop Gastroenterol. 17(4):197-198, 202-211; Gan, J. H. et al. (2005) “<i>Hybrid Artificial Liver Support System For Treatment Of Severe Liver Failure,”</i> World J Gastroenterol. 11 (6):890-894; Fukuda, J. et al. (2004) “<i>Hepatocyte Organoid Culture In Elliptic Hollow Fibers To Develop A Hybrid Artificial Liver,”</i> Int J Artif Organs. 27(12): 1091-1099; Meng, Q. et al. (2004) “<i>Hepatocyte Culture In Bioartificial Livers With Different Membrane Characteristics,”</i> Biotechnol Lett. 26(18):1407-1412; Sekido, H. et al. (2004) “<i>Usefulness Of Artificial Liver Support For Pretransplant Patients With Fulminant Hepatic Failure,”</i> Transplant Proc. 36(8):2355-2356; WO03/105663A2, WO05/000376A2, and U.S. Pat. No. 6,759,245. Hepatocyte transplantation is described by Chan, C. et al. (2004) “<i>Hepatic Tissue Engineering For Adjunct And Temporary Liver Support: Critical Technologies,” Liver Transpl. </i>10(11): 1331-1342; Lee, S. W. et al. (2004) “<i>Hepatocyte Transplantation: State Of The Art And Strategies For Overcoming Existing Hurdles,” Ann. Hepatol. </i>3(2):48-53; Horslen, S. P. (2004) “<i>Hepatocyte Transplantation,” Transplantation </i>77(10):1481-1486; Burlina, A. B. (2004) “<i>Hepatocyte Transplantation For Inborn Errors Of Metabolism,” J. Inherit. Metab. Dis. </i>27(3):373-83; and Fox, I. J. et al. (2004) “<i>Hepatocyte Transplantation,” Am. J. Transplant. </i>4 Suppl. 6:7-13.</p>
    <p num="p-0006">A limiting factor in the development of such model systems and to the development of Bioartificial Livers (BALs) has been the erratic source and limited availability of hepatocytes, especially human hepatocytes. Fresh hepatocytes are obtainable only from liver resections or non-transplantable livers of multi-organ donors (Lloyd, T. D. R. et al. (2003) <i>Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking </i>4:3-15). The supply of such tissue is inconsistent and often geographically inconvenient in light of the limited functional lifespan of liver tissue (Smrzova, J. et al. (2001) “<i>Optimization Of Porcine Hepatocytes Cryopreservation By Comparison Of Viability And Enzymatic Activity Of Fresh And Cryopreserved Cells,</i>” Acta Veterinaria Brunensis 70:141-147).</p>
    <p num="p-0007">One approach to addressing this problem has involved the development of hepatocyte storage conditions that allow hepatocytes to be maintained over time with their cellular functions preserved. Cryopreservation methods for the storage of hepatocytes have been developed to address this need (see, Lloyd, T. D. R. et al. (2003) <i>Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking </i>4:3-15; Loretz, L. J. et al. (1989) “<i>Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes,” </i>Xenobiotica. 19(5):489-498; Shaddock, J, G. et al. (1993) “<i>Cryopreservation And Long</i>-<i>Term Storage Of Primary Rat Hepatocytes: Effects On Substrate</i>-<i>Specific Cytochrome P</i>450-<i>Dependent Activities And Unscheduled DNA Synthesis,</i>” Cell Biol Toxicol. 9(4):345-357; Novicki, D. L. et al. (1982) “<i>Cryopreservation Of Isolated Rat Hepatocytes,</i>” In Vitro. 18(4):393-399; Zaleski, J. et al. (1993) “<i>Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen ,</i>” Biochem Pharmacol. 46(1):111-116). Typically, such measures comprise storage in liquid nitrogen (−196° C.) or in frozen nitrogen gas (−150° C.). The ability to recover viable thawed cells has been found to depend on multiple factors such as the rate of freezing, the concentration of hepatocytes, the type of cryoprotectant employed, and the final cooling temperature. Cell concentrations of 10<sup>6</sup>-10<sup>7 </sup>cells/ml have been typically employed. The isolated hepatocytes are typically incubated in suspension for a period (e.g., 4-48 hours) to allow them to recover from the isolation process. Thereafter, a cryoprotectant (such as glycerol, DMSO, polyvinylpyrrolodine, or dextran) is added, and the hepatocytes are frozen. The art has developed various freezing procedures, all designed to minimize or prevent the occurrence of intracellular ice. The freezing rates typically vary from −0.05° C./min to −50° C./min (see, Lloyd, T. D. R. et al. (2003) <i>Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking </i>4:3-15).</p>
    <p num="p-0008">While the development of cryopreservation methods for the storage of hepatocytes has significantly facilitated the availability of human hepatocytes, cryopreservation has been found to cause a significant decrease in cellular viability (e.g., 25-35%) (Dou, M. et al. (1992) “<i>Thawed Human Hepatocytes In Primary Culture,” </i>Cryobiology 29:454-469; Alexandre, E. et al. (2002) “<i>Cryopreservation Of Adult Human Hepatocytes Obtained From Resected Liver Biopsies,” </i>Cryobiology 44:103-113). Coundouris, J. A. et al. (1993) reported viability of 67% after 24 hours, declining to 49% after 14 days (Coundouris, J.A. et al. (1993) “<i>Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies,” </i>Xenobiotica. 23(12):1399-1409). Adams, R. M. et al. have reported that the viability of hepatocytes may be enhanced to greater than 90% using specialized cyropreservation fluids, however, only 16% of cells were found to be capable of replication (Adams, R. M. et al. (1995) “<i>Effective Cryopreservation And Long</i>-<i>Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential,” </i>Cell Transplant. 4(6):579-586). Methods of cryopreservation are disclosed in U.S. Pat. Nos. 5,795,711, 6,136,525, 5,895,745; International Patent Publications WO04/009766, WO92/12722, WO/0153462, European Patent No. EP0834252B, and U.S. Patent Application Publication Nos. US20020039786A1, US20030134418A1. The poor recovery of cells when cryopreserved continues to limit the use of hepatocytes in in vitro liver models.</p>
    <p num="p-0009">A second major problem affecting the use of both fresh and cryopreserved hepatocytes is the variation of liver enzyme expression that is observed in tissue from different donors (Li, A. P. et al. (1999) “<i>Present Status Of The Application Of Cryopreserved Hepatocytes In The Evaluation Of Xenobiotics: Consensus Of An International Expert Panel,”</i> Chem Biol Interact. 121(1):117-123; Li, A. P. et al. (1999) “<i>Cryopreserved Human Hepatocytes: Characterization Of Drug</i>-<i>Metabolizing Enzyme Activities And Applications In Higher Throughput Screening Assays For Hepatotoxicity, Metabolic Stability And Drug</i>-<i>Drug Interaction Potential,” </i>Chem Biol Interact. 121(1):17-35; O'Brien, Z. Z. et al. (undated) “<i>The Construction Of A Representative Human Cryopreserved Hepatocyte Pool For Metabolism Study.” </i>One solution to this sample variation involves pooling samples from different sources to produce a “composite” hepatocyte preparation having the characteristics of “average” liver cells. However, the frequency of receipt of fresh tissue and the need to cryopreserve hepatocytes immediately after isolation has been cited as preventing the preparation of hepatocyte pools. Thus, multiple companies (e.g., Xenotech, LLC; BD Biosciences) refrain from selling pooled hepatocytes thus forcing the end user to thaw and pool hepatocytes from several different donors. This difficulty remains even though pooled cryopreserved human hepatocytes are a valid model for metabolic studies (Zhang, J. G. et al. (undated) “<i>Validation Of Pooled Cryopreserved Human Hepatocytes As A Model For Metabolic Studies.”</i> </p>
    <p num="p-0010">Thus, despite all prior advances, a need remains for processes that would enable the availability of hepatocytes for medical research and other purposes. A need further exists for a stable and reproducible source of human hepatocytes. The present invention permits the production and availability of hepatocyte preparations that may be repeatedly cryopreserved and thawed without unacceptable loss of viability. The invention thus permits multiple hepatocyte samples to be pooled to produce pooled hepatocyte preparations, especially pooled cryopreserved human hepatocyte preparations. Using such advance, pooled cryopreserved human hepatocytes are now commercially available from In Vitro Technologies (Baltimore, Md.).</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p num="p-0011">The present invention relates to novel cell (e.g., hepatocyte) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.</p>
    <p num="p-0012">In detail, the invention particularly concerns a multi-cryopreserved hepatocyte preparation comprising hepatocytes that have been frozen and thawed at least two times, wherein greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable.</p>
    <p num="p-0013">The invention further concerns the embodiment of such a multi-cryopreserved hepatocyte preparation wherein the hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.</p>
    <p num="p-0014">The invention further concerns the embodiment of such a multi-cryopreserved hepatocyte preparation wherein the preparation comprises a pooled preparation of hepatocytes of multiple sources, which may be of the same or different gender, race, or health state, or which provide the pooled preparation with a desired level of a metabolic activity (especially wherein the metabolic activity is selected from the group consisting of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and CZX).</p>
    <p num="p-0015">The invention further concerns a method of producing a desired preparation of multi-cryopreserved hepatocytes, the hepatocytes being capable of being frozen and thawed at least two times, and in which greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable, the method comprising:
</p> <ul> <li id="ul0001-0001" num="0000"> <ul> <li id="ul0002-0001" num="0015">(A) subjecting hepatocytes that have been frozen and thawed to density gradient fractionation (especially percoll density centrifugation) to separate viable hepatocytes from non-viable hepatocytes,</li> <li id="ul0002-0002" num="0016">(B) recovering the separated viable hepatocytes, and</li> <li id="ul0002-0003" num="0017">(C) cryopreserving the recovered viable hepatocytes to thereby form the desired preparation of hepatocytes.</li> </ul> </li> </ul> <p num="p-0016">The invention further concerns the embodiment of such a method in which the hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.</p>
    <p num="p-0017">The invention further concerns the embodiment of such a method in which the preparation comprises a pooled preparation of hepatocytes of multiple sources, which may be of the same or different gender, race, or health state, or which provide the pooled preparation with a desired level of a metabolic activity (especially wherein the metabolic activity is selected from the group consisting of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and CZX).</p>
    <p num="p-0018">The invention also concerns a method of investigating in vitro drug metabolism comprising incubating hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence of a xenobiotic, and determining the metabolic fate of the xenobiotic, or the effect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity thereof, wherein the hepatocytes have been frozen and thawed at least two times, and wherein greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable.</p>
    <heading>DESCRIPTION OF THE PREFERRED EMBODIMENTS</heading> <p num="p-0019">The present invention relates to novel cell compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The methods of the present invention are generally applicable to a wide variety of cell types, including hepatocytes, kidney cells, spleen cells, thymus cells, bone marrow cells, stem cells, muscle cells (including cardiac muscle cells), endocrine cells (including pancreatic cells, adrenal cells, thyroid cells, etc.) epidermal cells, endodermal cells, etc. The methods of the present invention are illustrated below with respect to a preferred cell type: hepatocytes.</p>
    <p num="p-0020">The invention also concerns preparations of cells, e.g., hepatocytes, that have been repeatedly cryopreserved and thawed to obtain a high viability preparation useful for a variety of experimental, diagnostic and therapeutic purposes. The present invention extends the ability of hepatocytes to be cryopreserved and thawed for later use, so as to permit hepatocyte preparations to be repeatedly cryopreserved and thawed without an unacceptable loss of viability.</p>
    <p num="p-0021">As used herein, the term “cell preparation” denotes a liquid or frozen composition of cells from one or more sources (e.g., “hepatocyte preparation” denotes a composition of liver cells from one or more sources). The sources may be primary cells that have been dissociated from or isolated from tissue as by resection, biopsy, or from donor organs, or they may be secondary, immortalized or transformed cell cultures. The cells may be derived from any mammalian source, including human, porcine, simian, canine, feline, bovine, equine, ovine or rodent sources. The use of human, porcine or rodent (especially rat) cells is preferred. Preferably, greater than 50% and more preferably 70% or more of the hepatocytes of such preparations will be viable.</p>
    <p num="p-0022">As used herein, the term “multi-cryopreserved cell preparation” denotes a cell preparation that has been frozen and then thawed at least two times (e.g., a “multi-cryopreserved hepatocyte preparation” denotes a hepatocyte preparation that has been frozen and then thawed at least two times). Such preparations may have been frozen and thawed three, four, five, or more times.</p>
    <p num="p-0023">The term “pooled preparation” denotes a cell ( e.g., hepatocyte) preparation in which the cells (e.g., hepatocytes) are derived from two, three, four, five, or more different sources, such as different donors, biopsies, tissue resections from different tissue samples or different tissue sources, or different primary, secondary, immortalized or transformed cell (e.g., hepatocyte) cultures. The cells of such pooled preparations may be randomly selected cell, or may have been selected to provide the pooled preparation with a desired level of one or more metabolic activities (such as for example, a preparation of hepatocytes having a desired level of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and/or CZX activity), or a desired cell characteristic (such as, for example, a preparation of hepatocytes derived from sources of the same gender, age, race (e.g., Caucasian, etc.), or health state (e.g., hepatocytes of hepatitis virus-infected liver, hepatocytes of HIV-1 infected liver, hepatocytes of healthy liver, hepatocytes of cigarette smokers, hepatocytes of individuals suffering from cirrhosis of the liver, or from other diseases or conditions). For example, to obtain a pooled hepatocyte preparation with minimal DEX activity, a pooled preparation could be prepared from Lot. Nos. 067, CEK, ETR, PFM, VTA, or WWM (see, Table III).</p>
    <p num="p-0024">In a preferred embodiment, illustrated with respect to hepatocyte cells, the practice of the invention comprises some or all of the following steps: the isolation of hepatocytes, a first cryopreservation of the isolated primary hepatocytes to obtain a first cryopreserved hepatocyte preparation, the thawing of the first cryopreserved hepatocyte preparation to obtain viable hepatocytes, and the reformulation of the thawed viable hepatocytes to permit their further storage and use through repeated cryopreservation and thawing to obtain viable hepatocytes.</p>
    <p num="h-0005">The Isolation of Hepatocytes</p>
    <p num="p-0025">Any of a wide variety of methods may be employed or adapted to permit the isolation of the primary hepatocytes used in the present invention. For example, suitable techniques for the isolation of hepatocytes are outlined in Morsiani et al., (1995) “<i>Automated Liver Cell Processing Facilitates Large Scale Isolation And Purification Of Porcine Hepatocytes,” ASAIO Journal </i>41:155-161 and in Seglen, P. O. (1976) “<i>Preparation Of Isolated Rat Liver Cells,” </i>Meth. Cell Biol. 13:29-83). Specific reference is made to the two-step collagenase digestion procedure described in Li, A. P. et al. (1992) “<i>Isolation And Culturing Of Hepatocytes From Human Liver,” </i>J. Tissue Cult. Meth. 14:139-146.</p>
    <p num="p-0026">The hepatocytes may be cultured in any suitable hepatocyte culture medium. By way of illustration and not limitation mention may be made of the following culture media Chee's Essential Media (Hamilton, G. A. et al. (2001) “<i>Effects Of Medium Composition On The Morphology And Function Of Rat Hepatocytes Cultured As Spheroids And Monolayers,” </i>In Vitro Cell Dev Biol Anim. 37(10):656-667; Zurlo, J. et al. (1996) “<i>Characterization Of A Primary Hepatocyte Culture System For Toxicological Studies,” </i>In Vitro Cell Dev Biol Anim. 32(4):211-220; Arterburn, L. M. et al. (1995) “<i>A Morphological Study Of Differentiated Hepatocytes In Vitro,” </i>Hepatology 22(1):175-187), Modified Eagle Medium (or Dulbecco's Modified Eagle Medium) (Arikura, J. et al. (2002) “<i>UW Solution: A Promising Tool For Cryopreservation Of Primarily Isolated Rat Hepatocytes,” </i>J Hepatobiliary Pancreat Surg. 9(6):742-749; Washizu, J. et al. (2000) “<i>Amino Acid Supplementation Improves Cell</i>-<i>Specific Functions Of The Rat Hepatocytes Exposed To Human Plasma,” </i>Tissue Eng. 6(5):497-504; Iwata, H. et al. (1999) “<i>In Vitro Evaluation Of Metabolic Functions Of A Bioartificial Liver,” </i>ASAIO J. 45(4):299-306; Stutenkemper, R. et al. (1992) “<i>The Hepatocyte</i>-<i>Specific Phenotype Of Murine Liver Cells Correlates With High Expression Of Connexin</i>32 <i>And Connexin</i>26 <i>But Very Low Expression Of Connexin</i>43,” Exp Cell Res. 201(1):43-54), Leibowitz medium (Coundouris, J. A. et al. (1993) “<i>Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies,” </i>Xenobiotica. 23(12):1399-1409), Waymouth (Vind, C. et al. (1992) “<i>Regulation By Growth Hormone And Glucocorticoid Of Testosterone Metabolism In Long</i>-<i>Term Cultures Of Hepatocytes From Male And Female Rats,” </i>Biochem Pharmacol. 44(8):1523-1528; Nemoto, N. et al. (1991) “<i>Proline Is Required For Transcriptional Control Of The Aromatic Hydrocarbon</i>-<i>Inducible P</i>(1)450 <i>Gene In C</i>57<i>BL/</i>6 <i>Mouse Monolayer</i>-<i>Cultured Hepatocytes,” </i>Jpn J Cancer Res. 82(8):901-908; Dich, J. et al. (1988) “<i>Long</i>-<i>Term Culture Of Hepatocytes: Effect Of Hormones On Enzyme Activities And Metabolic Capacity,” </i>Hepatology. 8(1):39-45; Goethals, F. et al. (1984) “<i>Critical Biochemical Functions Of Isolated Hepatocytes As Sensitive Indicators Of Chemical Toxicity,” </i>Fundam Appl Toxicol. 4(3 Pt 1):441-450), Kreb's medium (House, J. D. (2001) “<i>Threonine Metabolism In Isolated Rat Hepatocytes,” </i>Am J Physiol Endocrinol Metab. 281(6):E1300-1307; Irvine, F. et al. (1993) “<i>Extracellular Calcium Modulates Insulin's Action On Enzymes Controlling Cyclic AMP Metabolism In Intact Hepatocytes,” </i>Biochem J. 293 (Pt 1):249-253; Marsh, D. C. et al. (1991) “<i>Hypothermic Preservation Of Hepatocytes. III. Effects Of Resuspension Media On Viability After Up To </i>7 <i>Days Of Storage,” </i>Hepatology 13(3):500-508), etc.</p>
    <p num="p-0027">In a preferred embodiment, hepatocytes are cryopreserved in a medium containing approximately 10% DMSO and approximately 90% fetal bovine serum (Loretz, L. J. et al. (1989) “<i>Optimization Of Cryopreservation Procedures For Rat And Human </i>Hepatocytes,” <i>Xenobiotica </i>19:489-498; Ruegg, C. E. et al. (1997) “<i>Cytochrome</i>-<i>P</i>450 <i>Induction and Conjugated Metabolism In Primary Human Hepastocytes After Cryopresevation,”</i> In Vitro Toxicol. 10:217-222).</p>
    <p num="p-0028">The viability of the isolated hepatocytes may be determined using any of a variety or methods. Preferable, such viability will be determined using the Trypan blue exclusion method (see, e.g., Berry, M. N. et al. (1992) “<i>Techniques For Pharmacological And Toxicological Studies With Isolated Hepatocyte Suspensions,” </i>Life Sci. 51(1):1-16). Thus the phrases “viable hepatocytes” or “percent viability”, as used herein, refers to hepatocyte viability as assessed using the method of Trypan Blue exclusion.</p>
    <p num="h-0006">Cryopreservation of the Isolated Primary Hepatocytes</p>
    <p num="p-0029">The hepatocytes of the present invention are preferably cryopreserved using liquid nitrogen, and most preferably within 36 hours of their isolation. Considerations for the cryopreservation of human hepatocytes are discussed in Lloyd, T. D. R. et al. (2003) <i>Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking,” Cell and Tissue Culture Banking </i>4:3-15. Suitable procedures for the cryopreservation of hepatocytes may also be found in the following documents: Adams, R. M. et al. (1995) “<i>Effective Cryopreservation And Long</i>-<i>Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential,” </i>Cell Transplant. 4(6):579-586; Chesne, C. et al. (1993) “<i>Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation,” </i>Hepatology 18(2):406-414; Coundouris, J. A. et al. (1993) “<i>Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies,” Xenobiotica. </i>23(12):1399-1409; Hewitt, N. J. et al. (2004) <i>Cryopreserved Rat, Dog And Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures,” Hum Exp Toxicol. </i>23(6):307-316; Novicki, D. L. et al. (1982) “<i>Cryopreservation Of Isolated Rat Hepatocytes,” </i>In Vitro. 18(4):393-399; Shaddock, J, G. et al. (1993) “<i>Cryopreservation And Long</i>-<i>Term Storage Of Primary Rat Hepatocytes: Effects On Substrate</i>-<i>Specific Cytochrome P</i>450-<i>Dependent Activities And Unscheduled DNA Synthesis,” </i>Cell Biol Toxicol. 9(4):345-357; Zaleski, J. et al. (1993) “<i>Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen,” </i>Biochem Pharmacol. 46(1):111-116.</p>
    <p num="p-0030">Preferably, isolated hepatocytes are suspended in a cryoprotective medium, and the suspended cells are dispensed into freezer-safe containers. A cryoprotective medium typically comprises a hepatocyte culture medium that contains at least one cryoprotectant that minimizes the deleterious effects of cryopreservation such as the formation of intracellular ice during freezing. By way of illustration and not limitation, the following commonly used cryoprotectants are listed: dimethylsulfoxide (DMSO), polyethylene glycol, amino acids, propanediol, and glycerol. A preferred cryoprotectant of the present invention is DMSO. Suitable cryoprotectants and methods for their use in hepatocyte cryopreservation can be found, for example, in: Loretz, L. J. et al. (1989) “<i>Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes,” </i>Xenobiotica. 19(5):489-498; Chesne, C. et al. (1993) “<i>Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation,” </i>Hepatology 18(2):406-414; Diener, B. et al. (1993) “<i>A Method For The Cryopreservation Of Liver Parenchymal Cells For Studies Of Xenobiotics,” </i>Cryobiology 30(2):116-127; Lawrence, J. N. et al. (1991) “<i>Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture. Toxicology In Vitro,” </i>5(1):39-51; Houle, r. et al. (2003) “<i>Retention of Transporter Activities in Cryopreserved. Isolated Rat Hepatocytes,” </i>Drug Metab. Disposit. 31(4):447-451; Silva, J. M. et al. (1999) “<i>Induction Of Cytochrome</i>-<i>P</i>450 <i>In Cryopreserved Rat And Human Hepatocytes,” </i>Chem-Biol Interact 121:49-63.</p>
    <p num="p-0031">The isolated hepatocytes are preferably suspended in a cryoprotective medium in preparation for freezing. The suspended cells are preferably dispensed into freezer resistant containers at a cell density of from about 10<sup>6 </sup>cells/ml to about 4×10<sup>7 </sup>cells/ml. Preferred freezing volumes range from 0.1-10.0 ml. The preferred freezing volume is 1.0 ml.</p>
    <p num="p-0032">The dispensed hepatocytes are then preferably cryopreserved using a controlled rate freezing process, most preferably at a freezing rate of between about −1° C./min to about −25° C./min until a final temperature of about −90° C. is reached. During the initial phase of the cryopreservation process, seeding may be employed to induce controlled crystallization or ice formation in cell suspensions that have already been cooled to below the freezing point of the culture medium. Such seeding serves to minimize ice formation-related damage and therefore may be beneficial to cell viability. Suitable seeding methods include inserting a cold metal rod into the freezing containers, and introducing a blast of liquid nitrogen into the freezing containers.</p>
    <p num="p-0033">Once the desired final temperature has been reached, the frozen cell samples may be transferred to liquid nitrogen freezers for prolonged storage. The frozen samples may be stored in either the liquid nitrogen phase or the gas phase of liquid nitrogen. Preferably storage is accomplished in the gas phase of liquid nitrogen. The frozen samples may be stored in this manner for days, months, or years, with the length of storage in the gas phase of liquid nitrogen having little effect on the post-thaw viability and function.</p>
    <p num="h-0007">The Thawing of Cryopreserved Hepatocytes</p>
    <p num="p-0034">Frozen samples may be thawed for further processing by removing them from the presence of liquid nitrogen or liquid nitrogen vapor. Frozen samples are preferably thawed by placing the samples immediately into a prewarmed water bath having a temperature of between about 37° C. to about 42° C. Preferably, cells are thawed to at least the stage in which ice chunks can be dislodged when the sample container is inverted. The thawed cells are then preferably rapidly processed to remove the cells from contact with DMSO, for example by PERCOLL® (colloidal silica particles of 15-30 nm diameter (23% w/w in water) which have been coated with polyvinylpyrrolidone (PVP)) gradient centrifugation (as described below) or by sequential washings.</p>
    <p num="p-0035">In a preferred embodiment, the cells are thawed into Complete INVITROGRO™ CP medium (In Vitro Technologies, Baltimore, Md.; Roymans, D. et al. (2004) “<i>Determination Of Cytochrome P</i>450 <i>IA</i>2 <i>And Cytochrome P</i>4503<i>a</i>4 <i>Induction In Cryopreserved Human Hepatocytes,”</i> Biochem Pharmacol. 67(3):427-437) (hepatocyte plating medium, which contains water, Dulbecco's Modified Eagle Medium, sodium bicarbonate, HEPES, fructose, bovine serum albumin, sodium hydroxide, MEM non-essential amino acids, insulin, hydrocortisone, and newborn calf serum). The medium is prepared by thawing TORPEDO™ Antibiotic Mix (In Vitro Technologies, Baltimore, Md.) (a mixture of antibiotics selected to inhibit bacterial growth in hepatocyte cell cultures that contains penicillin, streptomycin, gentamicin, amikacin and fungizone) to 37° C. in a water bath until thawed, and then removed from the water bath. 1.0 ml of TORPEDO™ Antibiotic Mix is then mixed with 45 ml INVITROGRO™ CP medium. Following the addition of TORPEDO™ Antibiotic Mix, the shelf life for the complete medium is 7 days. When thawing a single vial, the INVITROGRO™ CP medium is prewarmed to approximately 37° C. 5 ml of warmed INVITROGRO™ CP medium is added to a sterile 50 ml conical tube. The vial of frozen hepatocytes is carefully removed from the freezer. If the vial was stored in the liquid phase, its cap is carefully removed, any liquid nitrogen present in the vial is decanted, and the cap is reclosed before placing the vial into the water bath. It is preferred to then immediately immerse the vial into a 37° C. water bath, and to shake the vial gently until the ice is entirely melted, but no longer than it takes to completely thaw the vial. It may be helpful to remove any labels from the vial so that it will be easier to view the vial contents. The thawed contents are then emptied into the pre-warmed INVITROGRO™ CP medium. 1.0 ml of pre-warmed INVITROGRO™ CP medium then is added to each vial to resuspend any remaining cells. The contents of the vial are then decanted or pipetted into the hepatocyte suspension. The hepatocytes are preferably resuspended by gently inverting the receiving container (e.g., vial, test tube, etc.) several (e.g., three) times.</p>
    <p num="p-0036">When thawing multiple vials, it is preferred that all of the vials be thawed in the water bath simultaneously. As before, the medium (preferably, INVITROGRO™ CP medium) should be warmed to 37° C. It is desirable to ensure that there is enough medium to permit 5 ml of pre-warmed INVITROGRO™ CP medium to be used for each vial of cryopreserved hepatocytes. After vials have thawed, their caps should be quickly removed and their contents poured into a sterile tube or beaker that contains at least 5 ml of pre-warmed INVITROGRO™ CP medium per vial thawed. For example, 25 ml of media is preferably employed for 5 vials in a container that can hold a volume of 50 ml.</p>
    <p num="p-0037">If desired, the total cell count and the number of viable cells may be determined using the Trypan Blue exclusion method. Cells may be diluted to 0.70×10<sup>6 </sup>viable cells/ml with INVITROGRO™ CP medium.</p>
    <p num="h-0008">The Reformulation of Thawed Hepatocytes to Permit Further Cryopreservation and Thawing</p>
    <p num="p-0038">One aspect of the present invention concerns the ability to reformulate the thawed cells so that they may be refrozen and rethawed on one or more subsequent occasions. Such multi-cryopreserved hepatocyte preparations have multiple uses. They may be used in bioartificial livers, liver cell transplants, liver assist devices, hepatocyte transplantations, and in vitro applications. In particular, multi-cryopreserved hepatocyte preparations may be used in in vitro drug metabolism studies (for example, in identifying hepatocytes with unique characteristics (e.g.,. metabolic polymorphisms, genetic polymorphisms, etc.), in studies on the metabolic fate of the xenobiotic and studies on the affect of the xenobiotic in altering the drug-metabolizing enzyme profile of the hepatocytes, in inhibition studies to determine the IC<sub>50 </sub>of xenobiotics on liver enzymes and functions (e.g. cholesterol metabolism), in gene induction studies with xenobiotics, in protein induction studies with xenobiotics, in toxicity assessment of xenobiotics on hepatocytes, transport studies with xenobiotics (e.g. studies on P-glycoprotein transport systems, organic ion transporters, organic cation transporters, etc.), in metabolic clearance studies with xenobiotics, and in efficacy assays (e.g. lipoprotein processing, gluconeogenesis, protein secretion etc.). Multi-cryopreserved hepatocyte preparations may also be used to study or propagate hepatitis viruses and other infectious viruses and agents. Recovered cells may be reformulated for use in DNA, mRNA or proteomic studies or in studies of metabolic polymorphisms. Multi-cryopreserved hepatocyte preparations may also be used in metabolic clearance studies and efficacy assays (e.g., lipoprotein processing, gluconeogenesis, protein secretion, etc.). Cells may be reformulated for use in seeding bioreactors for large scale incubations or as models for gene regulation via micro RNA, or for use in combination systems with other cell types (e.g. non-parenchymal cells from liver or cells from other sources, e.g. Caco-2 cells).</p>
    <p num="p-0039">In a preferred embodiment of the invention, such reformulation comprises separating viable and non-viable cells prior to a subsequent refreezing. Density gradient centrifugation is preferably employed for this purpose. For example, a 30% PERCOLL® gradient centrifugation procedure may be employed (Madan, A. et al. (1999) “Effect of Cryopreservation on Cytochrome P-450 Enzyme Induction in Cultured Rat Hepatocytes, Drug Metab. Dispos. 27(3):327-335; Sun, E. L. et al. (1990) “<i>Cryopreservation Of Cynomologus Monkey </i>(<i>Macaca fascicularis</i>) <i>Hepatocytes For Subsequent Culture And Protein Synthesis Studies,</i>” In Vitro Cell Development and Biology 25:147-150; Lawrence, J. N. et al. (1991) “<i>Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture,” </i>Toxicology In Vitro, 5(1):39-51; Dou, M. et al. (1992) “<i>Thawed Human Hepatocytes In Primary Culture,” </i>Cryobiology 29(4):454-469; Utesch, D. et al. (1992) “<i>Characterization Of Cryopreserved Rat Liver Parenchymal Cells By Metabolism Of Diagnostic Substrates And Activities Of Related Enzymes,” </i>Biochemical Pharmacology 44:309-315. For example, the thawed cells may be resuspended in a prewarmed (approximately 37° C.) 30% PERCOLL® isotonic fractionation buffer and then centrifuged at 100×g at room temperature for twenty minutes to pellet viable cells. The supernatant is discarded and the cells are resuspended in media for a subsequent cryopreservation step directly or for further processing prior to cryopreservation.</p>
    <p num="p-0040">Cryopreserved preparations that result from the freezing of a previously frozen-thawed preparation will preferably have a post-thaw cell viability of greater than 50% and more preferably 70% or more. Such high viabilities enable the present invention to accomplish the repeated freezing and thawing of hepatocytes without unacceptable losses of cells or the need for ever greater samples sources.</p>
    <p num="h-0009">Pooled Hepatocyte Preparations</p>
    <p num="p-0041">The capacity of the present invention to enable the repeated freezing and thawing of hepatocytes additionally facilitates the production of pooled hepatocyte preparations, especially pooled human hepatocyte preparations. As discussed above, individual liver samples yield hepatocytes having differing metabolic capabilities. In order to facilitate the reproducible use or study of hepatocytes, it is desirable to minimize hepatocyte differences attributable to such sample variation by pooling hepatocytes from different sources to obtain a composite or “average” hepatocyte preparation. Such composite hepatocyte preparations may thus be formulated so as to provide a preparation having the metabolic activities of an “average” hepatocyte sample or a preparation whose hepatocyte enzyme functions approximate the hepatocyte enzyme functions of freshly isolated hepatocytes. Such metabolic activities may include, for example, some or all of the following enzymatic activities: coumarin 7-hydroxylase (COUM), dextromethorphan O-demethylase (DEX), 7-ethoxycoumarin O-deethylase (ECOD), activities responsible for the phase II metabolism of 7-hydroxycoumarin (7-HCG and 7-HCS), mephenytoin 4-hydroxylase (MEPH), testosterone 6(β)-hydroxylase (TEST), tolbutamide 4-hydroxylase (TOLB), phenacetin O-deethylase (PHEN), or chlorzoxazone 6-hydroxylase (CZX). The substrates, methods of measurements and assay units for assays of such metabolic activities are provided in Table I.</p>
    <p num="p-0042">
      <tables id="TABLE-US-00001" num="00001"> <table frame="none" colsep="0" rowsep="0" pgwide="1" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="259pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE I</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Hepatocyte Metabolic Activities</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="4"> <colspec colname="1" colwidth="42pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="70pt" align="left"> </colspec> <colspec colname="4" colwidth="63pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Method of</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Abbreviation</td>
                <td class="description-td">Substrate/Assay</td>
                <td class="description-td">Measurement</td>
                <td class="description-td">Units</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">7-HCG</td>
                <td class="description-td">7-hydroxycoumarin</td>
                <td class="description-td">Phase II metabolism</td>
                <td class="description-td">pmol/min/10<sup>6 </sup>cells</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">glucuronide</td>
                <td class="description-td">of 7-hydroxycoumarin</td>
              </tr> <tr class="description-tr"> <td class="description-td">7-HCS</td>
                <td class="description-td">7-hydroxycoumarin sulfate</td>
                <td class="description-td">Phase II metabolism</td>
                <td class="description-td">pmol/min/10<sup>6 </sup>cells</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">of 7-hydroxycoumarin</td>
              </tr> <tr class="description-tr"> <td class="description-td">NAT1</td>
                <td class="description-td">p-aminobenzoic acid</td>
                <td class="description-td">N-acetylation of p-</td>
                <td class="description-td">nmol/mg/min</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">aminobenzoic acid</td>
              </tr> <tr class="description-tr"> <td class="description-td">NAT2</td>
                <td class="description-td">Sulfamethazine</td>
                <td class="description-td">N-acetylation of</td>
                <td class="description-td">nmol/mg/min</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Sulfamethazine</td>
              </tr> <tr class="description-tr"> <td class="description-td">VBTY</td>
                <td class="description-td">viability</td>
                <td class="description-td">Trypan Blue ™</td>
                <td class="description-td">percentage</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">exclusion</td>
              </tr> <tr class="description-tr"> <td class="description-td">AP</td>
                <td class="description-td">Alkaline Phosphatase</td>
                <td class="description-td">Sigma kit</td>
                <td class="description-td">units/mg protein</td>
              </tr> <tr class="description-tr"> <td class="description-td">GGT</td>
                <td class="description-td">gamma-glutamyl</td>
                <td class="description-td">GGT stain</td>
                <td class="description-td">positive</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">transpeptidase</td>
              </tr> <tr class="description-tr"> <td class="description-td">UGT1</td>
                <td class="description-td">7-hydroxycoumarin</td>
                <td class="description-td">Phase II metabolism</td>
                <td class="description-td">169 pmol/mg/min</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">of 7-hydroxycoumarin</td>
              </tr> <tr class="description-tr"> <td class="description-td">P450</td>
                <td class="description-td">cytochrome p450 content</td>
                <td class="description-td">carbon monoxide</td>
                <td class="description-td">Not determined for</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">difference spectrum</td>
                <td class="description-td">cryo hepatocytes</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">nmol/mg protein</td>
              </tr> <tr class="description-tr"> <td class="description-td">CZX</td>
                <td class="description-td">chlorzoxazone</td>
                <td class="description-td">chlorzoxazone 6-</td>
                <td class="description-td">31.1 pmol/mg/min*</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">hydroxylation</td>
              </tr> <tr class="description-tr"> <td class="description-td">COUM</td>
                <td class="description-td">coumarin</td>
                <td class="description-td">coumarin 7-</td>
                <td class="description-td">50.0 pmol/mg/min*</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">hydroxylation</td>
              </tr> <tr class="description-tr"> <td class="description-td">DEX</td>
                <td class="description-td">dextromethorphan</td>
                <td class="description-td">dextromethorphan O-</td>
                <td class="description-td">21.4 pmol/mg/min*</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">demethylation</td>
              </tr> <tr class="description-tr"> <td class="description-td">MEPH</td>
                <td class="description-td">mephenytoin</td>
                <td class="description-td">mephenytoin 4-</td>
                <td class="description-td">24.1 pmol/mg/min*</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">hydroxylation</td>
              </tr> <tr class="description-tr"> <td class="description-td">PHEN</td>
                <td class="description-td">phenacetin</td>
                <td class="description-td">phenacetin O-</td>
                <td class="description-td">28.9 pmol/mg/min*</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">deethylation</td>
              </tr> <tr class="description-tr"> <td class="description-td">TEST</td>
                <td class="description-td">testosterone</td>
                <td class="description-td">testosterone 6(beta)-</td>
                <td class="description-td">96.8 pmol/mg/min*</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">hydroxylation</td>
              </tr> <tr class="description-tr"> <td class="description-td">TOLB</td>
                <td class="description-td">tolbutamide</td>
                <td class="description-td">tolbutamide 4-</td>
                <td class="description-td">30.6 pmol/mg/min*</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">hydroxylation</td>
              </tr> <tr class="description-tr"> <td class="description-td">PROT</td>
                <td class="description-td">protein content</td>
                <td class="description-td">Pierce protein kit</td>
                <td class="description-td">Not determined for</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">cryo hepatocytes</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">mg/mL</td>
              </tr> <tr class="description-tr"> <td class="description-td">ECOD</td>
                <td class="description-td">ethoxycoumarin</td>
                <td class="description-td">7-ethoxycoumarin O-</td>
                <td class="description-td">37.3 pmol/mg/min*</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">deethylation</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0043">For example, preferred preparations of pooled hepatocytes will yield assay values within the ranges identified in Table II. Alternatively, the hepatocytes samples used to form the pooled preparation may be selected so as to maximize, minimize, or emphasize certain hepatocyte functions over other functions so as to yield a pooled preparation that exhibits a user desired profile of liver cell function(s).</p>
    <p num="p-0044">The pooled hepatocyte preparations of the present invention may comprise hepatocytes obtained from the same source at differing times, or from two or more different sources. Preferably, pooled hepatocyte preparations will result from the pooling of hepatocytes obtained from three, four, five, six or more different sources.</p>
    <p num="p-0045">Most preferably, the pooled hepatocyte preparations of the invention will comprise at least one population of hepatocytes that were cryopreserved prior to pooling. For example, a pooled hepatocyte preparation may comprise one or more hepatocyte specimens that were cryopreserved prior to pooling with one or more freshly isolated hepatocyte specimens. Alternatively, a pooled hepatocyte preparation may comprise only hepatocyte specimens that were previously cryopreserved. Table II provides the normal range (i.e., the range between Assay Minimum and Assay Maximum for each Assay). Table II values are derived data of the last 150+ lots of human cryopreserved hepatocytes</p>
    <p num="p-0046">
      <tables id="TABLE-US-00002" num="00002"> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE II</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Hepatocyte Assays</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Normal Range</td>
              </tr> <tr class="description-tr"> <td class="description-td">Assay</td>
                <td class="description-td">(pmol/min/10<sup>6 </sup>cells)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">coumarin 7-hydroxylation</td>
                <td class="description-td">1 to 154</td>
              </tr> <tr class="description-tr"> <td class="description-td">Dextromethorphan O-demethylation</td>
                <td class="description-td">0.5 to 96  </td>
              </tr> <tr class="description-tr"> <td class="description-td">7-ethoxycoumarin O-deethylation</td>
                <td class="description-td">1 to 154</td>
              </tr> <tr class="description-tr"> <td class="description-td">Phase I metabolism of 7-hydroxycoumarin</td>
                <td class="description-td">2 to 545</td>
              </tr> <tr class="description-tr"> <td class="description-td">Phase II metabolism of 7-hydroxycoumarin</td>
                <td class="description-td">0 to 110</td>
              </tr> <tr class="description-tr"> <td class="description-td">mephenytoin 4-hydroxylation</td>
                <td class="description-td">0.2 to 442  </td>
              </tr> <tr class="description-tr"> <td class="description-td">testosterone 6(beta)-hydroxylation</td>
                <td class="description-td">2 to 675</td>
              </tr> <tr class="description-tr"> <td class="description-td">tolbutamide 4-hydroxylation</td>
                <td class="description-td">1.8 to 82  </td>
              </tr> <tr class="description-tr"> <td class="description-td">phenacetin O-deethylation</td>
                <td class="description-td">1 to 125</td>
              </tr> <tr class="description-tr"> <td class="description-td">chlorzoxazone 6-hydroxylation</td>
                <td class="description-td">2 to 215</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0047">In certain embodiments of the invention, hepatocyte preparations will have assay values in the above stated ranges for at least three of, and preferably for at least four of, still more preferably for at least six of, and most preferably for at least eight of the following assays: the COUM assay; the DEX assay; the ECOD assay; the 7-HCG assay; the 7-HCS assay; the MEPH assay; the TEST assay; the TOLB assay; the PHEN assay; the CZX assay.</p>
    <p num="p-0048">If desired, the cryopreserved hepatocytes may be plated on to collagen-coated tissue culture plates, or tissue culture plates coated with other extracelluar matrix proteins including but not limited to laminin, fibronectin, entactin, poly-L-lysine, gelatin, or any combination thereof. Preferably, this is accomplished by diluting an appropriate volume (e.g., 0.2 ml to 2.5 ml) of diluted cells (e.g., cells having a concentration of approximately 0.7×10<sup>6 </sup>cells/ml) onto the plates. For plating on a 96-well microtiter plate, it is desirable to further dilute the cell suspension to a concentration of 0.35×10<sup>6 </sup>cells/ml with InVitroGRO CP medium, and to add 100 μl of the cell suspension to each well. It is preferred to even distribute the cells in the wells. This can be accomplished by gently shaking the plates in a back-and-forth and side-to-side manner; the use of a circular motion will cause the cells to unevenly pool in the center of the wells. Human hepatocytes handled in this manner will attach to the plates in 2-4 hours, however, if minimal handling is desired, the cells can be allowed to attach overnight.</p>
    <p num="p-0049">Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention unless specified.</p>
    <heading>EXAMPLE 1</heading> <heading>Refreezing of Thawed Hepatocyte Preparations</heading> <p num="p-0050">Cryopreserved hepatocytes are thawed and refrozen as indicated below.</p>
    <p num="p-0051">Materials: 30 cc syringe, two couplers, PERCOLL® in a 1 L bag, INVITROGRO™ CP-2 medium in a 2 L bag, 1-2 L autoclaved beaker, heater, waterbath, centrifuge tube rack.</p>
    <p num="p-0052">Procedure:
</p> <ul> <li id="ul0003-0001" num="0000"> <ul> <li id="ul0004-0001" num="0055">1) Set up a recirculating waterbath heater at 37-42° C.</li> <li id="ul0004-0002" num="0056">2) Add approximately 200-400 mls of INVITROGRO™ CP medium to a 1-2 L beaker. Equip Biological Safety Cabinet with a manual pipet or a liquid handling robot.</li> <li id="ul0004-0003" num="0057">3) Remove approximately 50 cryovials from dewar receptacle and quickly place them in 2 test tube racks. When possible, space vials apart.</li> <li id="ul0004-0004" num="0058">4) Submerge solid cell suspensions into heated waterbath until the ice chunks can be dislodged when the vial is inverted.</li> <li id="ul0004-0005" num="0059">5) Pour cell suspension from each vial into the beaker. Add 1 ml of INVITROGRO™ CP medium from the small beaker into each vial to rinse and pour contents into the beaker. Transfer thawed cell suspension into a 1 L sterile bag.</li> </ul> </li> </ul> <p num="p-0053">6) Attach bag, INVITROGRO™ CP medium in a 2 L bag and PERCOLL® bagged at 30% onto COBE® automated cell processor(a centrifugal system incorporating a flexible membrane that allows the removal of fluids while spinning through use of a rotating seal, hydraulic pump and flexible membrane) and process according to standard practices.</p>
    <p num="p-0054">7) Perform a cell count.</p>
    <p num="p-0055">8) Cryopreserve cell suspension.</p>
    <p num="p-0056">PERCOLL/REDIGRAD™ (Amersham Biosciences) is employed for the PERCOLL® density centrifugation. PERCOLL® is composed of colloidal silica coated with polyvinylpyrrolidone (PVP). The REDIGRAD™ formulation is also composed of colloidal silica but is covalently coated with silane. These coatings are thought to render the material non-toxic and ideal for use with biological materials. Both particles have a density of 1.13 g/ml. Centrifugation of sample in the presence of PERCOLL/REDIGRAD™ results in the spontaneous formation of a density gradient due to the heterogeneity of particle sizes in the medium.</p>
    <p num="p-0057">PERCOLL/REDIGRAD™ is best used in balanced salt solutions, such as physiological saline (0.15 M NaCl), although 0.25 M sucrose may be employed. The addition of 9 parts (v/v) of PERCOLL/REDIGRAD™ to 1 part (v/v) of either 1.5 M NaCl, 10× concentrated cell culture medium, or 2.5 M sucrose will result in a solution adjusted to about 340 mOs/kg H<sub>2</sub>O. Solutions of different osmotic pressure can be produced by adjusting the relative volumes of PERCOLL/REDIGRAD™ and salt or sucrose solution. (Vincent, R. et al. (1984) “<i>Adjustment Of The Osmolality Of Percoll For The Isopycnic Separation Of Cells And Cell Organelles,” </i>Anal. Biochem. 141(2):322-328). The final adjustment to the required osmolality can be carried out by the addition of salts or distilled water. Concentrations other than 10× physiological saline may also be used satisfactorily.</p>
    <p num="p-0058">PERCOLL/REDIGRAD™ will form self-generated gradients by centrifugation in fixed-angle rotor heads after 15 minutes. Hepatocytes can be separated by centrifugation at 50-100 g<sub>av </sub>in fixed-angle or swinging bucket rotor heads after 10-30 minutes.</p>
    <heading>EXAMPLE 2</heading> <heading>Variation of Primary Hepatocyte Samples</heading> <p num="p-0059">To illustrate the sample-to-sample variation of different sources of individual (unpooled) hepatocytes, hepatocytes are isolated from 82 different donors and analyzed for cell viability and enzyme function. The following metabolic activities are evaluated: COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, TOLB, PHEN, and CZX. The results are shown in Table III.</p>
    <p num="p-0060">
      <tables id="TABLE-US-00003" num="00003"> <table frame="none" colsep="0" rowsep="0" pgwide="1" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="315pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE III</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Variation of Hepatocyte Samples</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="13"> <colspec colname="1" colwidth="28pt" align="left"> </colspec> <colspec colname="2" colwidth="21pt" align="left"> </colspec> <colspec colname="3" colwidth="21pt" align="center"> </colspec> <colspec colname="4" colwidth="28pt" align="center"> </colspec> <colspec colname="5" colwidth="21pt" align="center"> </colspec> <colspec colname="6" colwidth="28pt" align="center"> </colspec> <colspec colname="7" colwidth="21pt" align="center"> </colspec> <colspec colname="8" colwidth="21pt" align="center"> </colspec> <colspec colname="9" colwidth="28pt" align="center"> </colspec> <colspec colname="10" colwidth="21pt" align="center"> </colspec> <colspec colname="11" colwidth="28pt" align="center"> </colspec> <colspec colname="12" colwidth="28pt" align="center"> </colspec> <colspec colname="13" colwidth="21pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">7-</td>
                <td class="description-td">7-</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Lot No.</td>
                <td class="description-td">Sex</td>
                <td class="description-td">% V</td>
                <td class="description-td">COUM</td>
                <td class="description-td">DEX</td>
                <td class="description-td">ECOD</td>
                <td class="description-td">HCG</td>
                <td class="description-td">HCS</td>
                <td class="description-td">MEPH</td>
                <td class="description-td">TEST</td>
                <td class="description-td">TOLB</td>
                <td class="description-td">PHEN</td>
                <td class="description-td">CZX</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="13" align="center" rowsep="1" class="description-td" colspan="13"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="13"> <colspec colname="1" colwidth="28pt" align="left"> </colspec> <colspec colname="2" colwidth="21pt" align="left"> </colspec> <colspec colname="3" colwidth="21pt" align="center"> </colspec> <colspec colname="4" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="5" colwidth="21pt" align="char" char="."> </colspec> <colspec colname="6" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="7" colwidth="21pt" align="char" char="."> </colspec> <colspec colname="8" colwidth="21pt" align="char" char="."> </colspec> <colspec colname="9" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="10" colwidth="21pt" align="char" char="."> </colspec> <colspec colname="11" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="12" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="13" colwidth="21pt" align="char" char="."> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">067</td>
                <td class="description-td">M</td>
                <td class="description-td">62%</td>
                <td class="description-td">67</td>
                <td class="description-td">1</td>
                <td class="description-td">70</td>
                <td class="description-td">231</td>
                <td class="description-td">24</td>
                <td class="description-td">2</td>
                <td class="description-td">44</td>
                <td class="description-td">35</td>
                <td class="description-td">27</td>
                <td class="description-td">24</td>
              </tr> <tr class="description-tr"> <td class="description-td">086</td>
                <td class="description-td">F</td>
                <td class="description-td">74%</td>
                <td class="description-td">51</td>
                <td class="description-td">23</td>
                <td class="description-td">10</td>
                <td class="description-td">50</td>
                <td class="description-td">9</td>
                <td class="description-td">1</td>
                <td class="description-td">38</td>
                <td class="description-td">13</td>
                <td class="description-td">BQL</td>
                <td class="description-td">18</td>
              </tr> <tr class="description-tr"> <td class="description-td">089</td>
                <td class="description-td">F</td>
                <td class="description-td">77%</td>
                <td class="description-td">25</td>
                <td class="description-td">21</td>
                <td class="description-td">8</td>
                <td class="description-td">23</td>
                <td class="description-td">6</td>
                <td class="description-td">1</td>
                <td class="description-td">11</td>
                <td class="description-td">13</td>
                <td class="description-td">BQL</td>
                <td class="description-td">29</td>
              </tr> <tr class="description-tr"> <td class="description-td">090</td>
                <td class="description-td">F</td>
                <td class="description-td">74%</td>
                <td class="description-td">30</td>
                <td class="description-td">25</td>
                <td class="description-td">7</td>
                <td class="description-td">13</td>
                <td class="description-td">BQL</td>
                <td class="description-td">2</td>
                <td class="description-td">19</td>
                <td class="description-td">15</td>
                <td class="description-td">BQL</td>
                <td class="description-td">16</td>
              </tr> <tr class="description-tr"> <td class="description-td">091</td>
                <td class="description-td">F</td>
                <td class="description-td">73%</td>
                <td class="description-td">13</td>
                <td class="description-td">29</td>
                <td class="description-td">66</td>
                <td class="description-td">44</td>
                <td class="description-td">10</td>
                <td class="description-td">12</td>
                <td class="description-td">252</td>
                <td class="description-td">36</td>
                <td class="description-td">27</td>
                <td class="description-td">36</td>
              </tr> <tr class="description-tr"> <td class="description-td">094</td>
                <td class="description-td">F</td>
                <td class="description-td">67%</td>
                <td class="description-td">41</td>
                <td class="description-td">12</td>
                <td class="description-td">37</td>
                <td class="description-td">24</td>
                <td class="description-td">4</td>
                <td class="description-td">21</td>
                <td class="description-td">126</td>
                <td class="description-td">40</td>
                <td class="description-td">19</td>
                <td class="description-td">87</td>
              </tr> <tr class="description-tr"> <td class="description-td">099</td>
                <td class="description-td">F</td>
                <td class="description-td">86%</td>
                <td class="description-td">21</td>
                <td class="description-td">15</td>
                <td class="description-td">7</td>
                <td class="description-td">4</td>
                <td class="description-td">BQL</td>
                <td class="description-td">1</td>
                <td class="description-td">60</td>
                <td class="description-td">10</td>
                <td class="description-td">BQL</td>
                <td class="description-td">22</td>
              </tr> <tr class="description-tr"> <td class="description-td">104</td>
                <td class="description-td">M</td>
                <td class="description-td">81%</td>
                <td class="description-td">63</td>
                <td class="description-td">21</td>
                <td class="description-td">44</td>
                <td class="description-td">247</td>
                <td class="description-td">25</td>
                <td class="description-td">2</td>
                <td class="description-td">58</td>
                <td class="description-td">37</td>
                <td class="description-td">8</td>
                <td class="description-td">20</td>
              </tr> <tr class="description-tr"> <td class="description-td">105</td>
                <td class="description-td">M</td>
                <td class="description-td">67%</td>
                <td class="description-td">59</td>
                <td class="description-td">15</td>
                <td class="description-td">24</td>
                <td class="description-td">38</td>
                <td class="description-td">14</td>
                <td class="description-td">1</td>
                <td class="description-td">29</td>
                <td class="description-td">27</td>
                <td class="description-td">12</td>
                <td class="description-td">27</td>
              </tr> <tr class="description-tr"> <td class="description-td">110</td>
                <td class="description-td">F</td>
                <td class="description-td">77%</td>
                <td class="description-td">45</td>
                <td class="description-td">24</td>
                <td class="description-td">35</td>
                <td class="description-td">23</td>
                <td class="description-td">4</td>
                <td class="description-td">6</td>
                <td class="description-td">206</td>
                <td class="description-td">11</td>
                <td class="description-td">54</td>
                <td class="description-td">36</td>
              </tr> <tr class="description-tr"> <td class="description-td">111</td>
                <td class="description-td">F</td>
                <td class="description-td">71%</td>
                <td class="description-td">4</td>
                <td class="description-td">10</td>
                <td class="description-td">9</td>
                <td class="description-td">2</td>
                <td class="description-td">3</td>
                <td class="description-td">3</td>
                <td class="description-td">147</td>
                <td class="description-td">2</td>
                <td class="description-td">19</td>
                <td class="description-td">19</td>
              </tr> <tr class="description-tr"> <td class="description-td">114</td>
                <td class="description-td">F</td>
                <td class="description-td">75%</td>
                <td class="description-td">39</td>
                <td class="description-td">23</td>
                <td class="description-td">21</td>
                <td class="description-td">10</td>
                <td class="description-td">5</td>
                <td class="description-td">5</td>
                <td class="description-td">59</td>
                <td class="description-td">TBD</td>
                <td class="description-td">3</td>
                <td class="description-td">45</td>
              </tr> <tr class="description-tr"> <td class="description-td">122</td>
                <td class="description-td">M</td>
                <td class="description-td">79%</td>
                <td class="description-td">26</td>
                <td class="description-td">30</td>
                <td class="description-td">29</td>
                <td class="description-td">80</td>
                <td class="description-td">5</td>
                <td class="description-td">1</td>
                <td class="description-td">42</td>
                <td class="description-td">23</td>
                <td class="description-td">4</td>
                <td class="description-td">25</td>
              </tr> <tr class="description-tr"> <td class="description-td">129</td>
                <td class="description-td">F</td>
                <td class="description-td">90%</td>
                <td class="description-td">4</td>
                <td class="description-td">24</td>
                <td class="description-td">27</td>
                <td class="description-td">67</td>
                <td class="description-td">18</td>
                <td class="description-td">1</td>
                <td class="description-td">16</td>
                <td class="description-td">33</td>
                <td class="description-td">10</td>
                <td class="description-td">51</td>
              </tr> <tr class="description-tr"> <td class="description-td">ACU</td>
                <td class="description-td">F</td>
                <td class="description-td">81%</td>
                <td class="description-td">53</td>
                <td class="description-td">8</td>
                <td class="description-td">25</td>
                <td class="description-td">74</td>
                <td class="description-td">18</td>
                <td class="description-td">8</td>
                <td class="description-td">80</td>
                <td class="description-td">16</td>
                <td class="description-td">4</td>
                <td class="description-td">23</td>
              </tr> <tr class="description-tr"> <td class="description-td">AIT</td>
                <td class="description-td">F</td>
                <td class="description-td">83%</td>
                <td class="description-td">45</td>
                <td class="description-td">29</td>
                <td class="description-td">13</td>
                <td class="description-td">118</td>
                <td class="description-td">14</td>
                <td class="description-td">BQL</td>
                <td class="description-td">82</td>
                <td class="description-td">15</td>
                <td class="description-td">11</td>
                <td class="description-td">7</td>
              </tr> <tr class="description-tr"> <td class="description-td">AOK</td>
                <td class="description-td">M</td>
                <td class="description-td">73%</td>
                <td class="description-td">60</td>
                <td class="description-td">21</td>
                <td class="description-td">58</td>
                <td class="description-td">283</td>
                <td class="description-td">64</td>
                <td class="description-td">5</td>
                <td class="description-td">86</td>
                <td class="description-td">30</td>
                <td class="description-td">24</td>
                <td class="description-td">21</td>
              </tr> <tr class="description-tr"> <td class="description-td">ATR</td>
                <td class="description-td">M</td>
                <td class="description-td">73%</td>
                <td class="description-td">7</td>
                <td class="description-td">11</td>
                <td class="description-td">1</td>
                <td class="description-td">39</td>
                <td class="description-td">11</td>
                <td class="description-td">BQL</td>
                <td class="description-td">11</td>
                <td class="description-td">8</td>
                <td class="description-td">3</td>
                <td class="description-td">4</td>
              </tr> <tr class="description-tr"> <td class="description-td">AVF</td>
                <td class="description-td">M</td>
                <td class="description-td">70%</td>
                <td class="description-td">59</td>
                <td class="description-td">13</td>
                <td class="description-td">50</td>
                <td class="description-td">210</td>
                <td class="description-td">29</td>
                <td class="description-td">BQL</td>
                <td class="description-td">54</td>
                <td class="description-td">37</td>
                <td class="description-td">11</td>
                <td class="description-td">24</td>
              </tr> <tr class="description-tr"> <td class="description-td">BTP</td>
                <td class="description-td">M</td>
                <td class="description-td">88%</td>
                <td class="description-td">66</td>
                <td class="description-td">29</td>
                <td class="description-td">36</td>
                <td class="description-td">214</td>
                <td class="description-td">25</td>
                <td class="description-td">3</td>
                <td class="description-td">50</td>
                <td class="description-td">45</td>
                <td class="description-td">11</td>
                <td class="description-td">12</td>
              </tr> <tr class="description-tr"> <td class="description-td">CEC</td>
                <td class="description-td">M</td>
                <td class="description-td">86%</td>
                <td class="description-td">47</td>
                <td class="description-td">26</td>
                <td class="description-td">17</td>
                <td class="description-td">105</td>
                <td class="description-td">27</td>
                <td class="description-td">21</td>
                <td class="description-td">32</td>
                <td class="description-td">57</td>
                <td class="description-td">38</td>
                <td class="description-td">36</td>
              </tr> <tr class="description-tr"> <td class="description-td">CEK</td>
                <td class="description-td">F</td>
                <td class="description-td">80%</td>
                <td class="description-td">55</td>
                <td class="description-td">2</td>
                <td class="description-td">39</td>
                <td class="description-td">141</td>
                <td class="description-td">5</td>
                <td class="description-td">16</td>
                <td class="description-td">302</td>
                <td class="description-td">41</td>
                <td class="description-td">7</td>
                <td class="description-td">16</td>
              </tr> <tr class="description-tr"> <td class="description-td">CHD</td>
                <td class="description-td">F</td>
                <td class="description-td">77%</td>
                <td class="description-td">30</td>
                <td class="description-td">14</td>
                <td class="description-td">53</td>
                <td class="description-td">471</td>
                <td class="description-td">42</td>
                <td class="description-td">4</td>
                <td class="description-td">28</td>
                <td class="description-td">23</td>
                <td class="description-td">13</td>
                <td class="description-td">26</td>
              </tr> <tr class="description-tr"> <td class="description-td">CPN</td>
                <td class="description-td">M</td>
                <td class="description-td">81%</td>
                <td class="description-td">28</td>
                <td class="description-td">6</td>
                <td class="description-td">40</td>
                <td class="description-td">100</td>
                <td class="description-td">13</td>
                <td class="description-td">2</td>
                <td class="description-td">168</td>
                <td class="description-td">14</td>
                <td class="description-td">37</td>
                <td class="description-td">21</td>
              </tr> <tr class="description-tr"> <td class="description-td">ECM</td>
                <td class="description-td">M</td>
                <td class="description-td">85%</td>
                <td class="description-td">8</td>
                <td class="description-td">11</td>
                <td class="description-td">10</td>
                <td class="description-td">55</td>
                <td class="description-td">18</td>
                <td class="description-td">6</td>
                <td class="description-td">81</td>
                <td class="description-td">18</td>
                <td class="description-td">21</td>
                <td class="description-td">9</td>
              </tr> <tr class="description-tr"> <td class="description-td">EFA</td>
                <td class="description-td">M</td>
                <td class="description-td">69%</td>
                <td class="description-td">9</td>
                <td class="description-td">9</td>
                <td class="description-td">35</td>
                <td class="description-td">47</td>
                <td class="description-td">5</td>
                <td class="description-td">18</td>
                <td class="description-td">66</td>
                <td class="description-td">12</td>
                <td class="description-td">47</td>
                <td class="description-td">67</td>
              </tr> <tr class="description-tr"> <td class="description-td">EHI</td>
                <td class="description-td">F</td>
                <td class="description-td">90%</td>
                <td class="description-td">88</td>
                <td class="description-td">3</td>
                <td class="description-td">56</td>
                <td class="description-td">291</td>
                <td class="description-td">45</td>
                <td class="description-td">1</td>
                <td class="description-td">248</td>
                <td class="description-td">21</td>
                <td class="description-td">45</td>
                <td class="description-td">43</td>
              </tr> <tr class="description-tr"> <td class="description-td">EJR</td>
                <td class="description-td">F</td>
                <td class="description-td">75%</td>
                <td class="description-td">89</td>
                <td class="description-td">14</td>
                <td class="description-td">32</td>
                <td class="description-td">288</td>
                <td class="description-td">43</td>
                <td class="description-td">8</td>
                <td class="description-td">62</td>
                <td class="description-td">41</td>
                <td class="description-td">1</td>
                <td class="description-td">41</td>
              </tr> <tr class="description-tr"> <td class="description-td">ENR</td>
                <td class="description-td">M</td>
                <td class="description-td">73%</td>
                <td class="description-td">69</td>
                <td class="description-td">28</td>
                <td class="description-td">27</td>
                <td class="description-td">124</td>
                <td class="description-td">31</td>
                <td class="description-td">107</td>
                <td class="description-td">77</td>
                <td class="description-td">36</td>
                <td class="description-td">38</td>
                <td class="description-td">32</td>
              </tr> <tr class="description-tr"> <td class="description-td">EOB</td>
                <td class="description-td">M</td>
                <td class="description-td">88%</td>
                <td class="description-td">14</td>
                <td class="description-td">11</td>
                <td class="description-td">18</td>
                <td class="description-td">65</td>
                <td class="description-td">9</td>
                <td class="description-td">31</td>
                <td class="description-td">49</td>
                <td class="description-td">14</td>
                <td class="description-td">21</td>
                <td class="description-td">35</td>
              </tr> <tr class="description-tr"> <td class="description-td">ETR</td>
                <td class="description-td">F</td>
                <td class="description-td">88%</td>
                <td class="description-td">30</td>
                <td class="description-td">1</td>
                <td class="description-td">34</td>
                <td class="description-td">13</td>
                <td class="description-td">13</td>
                <td class="description-td">7</td>
                <td class="description-td">13</td>
                <td class="description-td">13</td>
                <td class="description-td">37</td>
                <td class="description-td">69</td>
              </tr> <tr class="description-tr"> <td class="description-td">EVY</td>
                <td class="description-td">M</td>
                <td class="description-td">80%</td>
                <td class="description-td">2</td>
                <td class="description-td">20</td>
                <td class="description-td">23</td>
                <td class="description-td">218</td>
                <td class="description-td">77</td>
                <td class="description-td">33</td>
                <td class="description-td">24</td>
                <td class="description-td">25</td>
                <td class="description-td">17</td>
                <td class="description-td">38</td>
              </tr> <tr class="description-tr"> <td class="description-td">FNL</td>
                <td class="description-td">M</td>
                <td class="description-td">85%</td>
                <td class="description-td">17</td>
                <td class="description-td">27</td>
                <td class="description-td">62</td>
                <td class="description-td">282</td>
                <td class="description-td">32</td>
                <td class="description-td">6</td>
                <td class="description-td">6</td>
                <td class="description-td">50</td>
                <td class="description-td">14</td>
                <td class="description-td">24</td>
              </tr> <tr class="description-tr"> <td class="description-td">FRW</td>
                <td class="description-td">M</td>
                <td class="description-td">75%</td>
                <td class="description-td">46</td>
                <td class="description-td">22</td>
                <td class="description-td">16</td>
                <td class="description-td">106</td>
                <td class="description-td">17</td>
                <td class="description-td">48</td>
                <td class="description-td">25</td>
                <td class="description-td">54</td>
                <td class="description-td">44</td>
                <td class="description-td">8</td>
              </tr> <tr class="description-tr"> <td class="description-td">GBE</td>
                <td class="description-td">F</td>
                <td class="description-td">77%</td>
                <td class="description-td">5</td>
                <td class="description-td">49</td>
                <td class="description-td">31</td>
                <td class="description-td">165</td>
                <td class="description-td">20</td>
                <td class="description-td">2</td>
                <td class="description-td">16</td>
                <td class="description-td">19</td>
                <td class="description-td">5</td>
                <td class="description-td">54</td>
              </tr> <tr class="description-tr"> <td class="description-td">GNG</td>
                <td class="description-td">F</td>
                <td class="description-td">74%</td>
                <td class="description-td">57</td>
                <td class="description-td">17</td>
                <td class="description-td">33</td>
                <td class="description-td">54</td>
                <td class="description-td">8</td>
                <td class="description-td">5</td>
                <td class="description-td">95</td>
                <td class="description-td">22</td>
                <td class="description-td">16</td>
                <td class="description-td">22</td>
              </tr> <tr class="description-tr"> <td class="description-td">GTV</td>
                <td class="description-td">F</td>
                <td class="description-td">71%</td>
                <td class="description-td">32</td>
                <td class="description-td">6</td>
                <td class="description-td">8</td>
                <td class="description-td">47</td>
                <td class="description-td">7</td>
                <td class="description-td">BQL</td>
                <td class="description-td">40</td>
                <td class="description-td">28</td>
                <td class="description-td">16</td>
                <td class="description-td">11</td>
              </tr> <tr class="description-tr"> <td class="description-td">GUY</td>
                <td class="description-td">M</td>
                <td class="description-td">92%</td>
                <td class="description-td">65</td>
                <td class="description-td">12</td>
                <td class="description-td">11</td>
                <td class="description-td">73</td>
                <td class="description-td">12</td>
                <td class="description-td">20</td>
                <td class="description-td">90</td>
                <td class="description-td">13</td>
                <td class="description-td">5</td>
                <td class="description-td">8</td>
              </tr> <tr class="description-tr"> <td class="description-td">HHG</td>
                <td class="description-td">M</td>
                <td class="description-td">83%</td>
                <td class="description-td">2</td>
                <td class="description-td">8</td>
                <td class="description-td">14</td>
                <td class="description-td">251</td>
                <td class="description-td">29</td>
                <td class="description-td">BQL</td>
                <td class="description-td">28</td>
                <td class="description-td">12</td>
                <td class="description-td">4</td>
                <td class="description-td">40</td>
              </tr> <tr class="description-tr"> <td class="description-td">HRU</td>
                <td class="description-td">M</td>
                <td class="description-td">90%</td>
                <td class="description-td">43</td>
                <td class="description-td">28</td>
                <td class="description-td">39</td>
                <td class="description-td">175</td>
                <td class="description-td">15</td>
                <td class="description-td">4</td>
                <td class="description-td">69</td>
                <td class="description-td">40</td>
                <td class="description-td">57</td>
                <td class="description-td">44</td>
              </tr> <tr class="description-tr"> <td class="description-td">ICJ</td>
                <td class="description-td">M</td>
                <td class="description-td">74%</td>
                <td class="description-td">134</td>
                <td class="description-td">20</td>
                <td class="description-td">60</td>
                <td class="description-td">287</td>
                <td class="description-td">17</td>
                <td class="description-td">BQL</td>
                <td class="description-td">129</td>
                <td class="description-td">82</td>
                <td class="description-td">28</td>
                <td class="description-td">7</td>
              </tr> <tr class="description-tr"> <td class="description-td">IEM</td>
                <td class="description-td">M</td>
                <td class="description-td">88%</td>
                <td class="description-td">34</td>
                <td class="description-td">17</td>
                <td class="description-td">23</td>
                <td class="description-td">129</td>
                <td class="description-td">34</td>
                <td class="description-td">72</td>
                <td class="description-td">48</td>
                <td class="description-td">23</td>
                <td class="description-td">19</td>
                <td class="description-td">34</td>
              </tr> <tr class="description-tr"> <td class="description-td">IHR</td>
                <td class="description-td">F</td>
                <td class="description-td">76%</td>
                <td class="description-td">17</td>
                <td class="description-td">43</td>
                <td class="description-td">8</td>
                <td class="description-td">84</td>
                <td class="description-td">9</td>
                <td class="description-td">9</td>
                <td class="description-td">95</td>
                <td class="description-td">46</td>
                <td class="description-td">41</td>
                <td class="description-td">7</td>
              </tr> <tr class="description-tr"> <td class="description-td">LID</td>
                <td class="description-td">M</td>
                <td class="description-td">86%</td>
                <td class="description-td">36</td>
                <td class="description-td">31</td>
                <td class="description-td">50</td>
                <td class="description-td">307</td>
                <td class="description-td">54</td>
                <td class="description-td">1</td>
                <td class="description-td">142</td>
                <td class="description-td">49</td>
                <td class="description-td">21</td>
                <td class="description-td">51</td>
              </tr> <tr class="description-tr"> <td class="description-td">IRX</td>
                <td class="description-td">F</td>
                <td class="description-td">73%</td>
                <td class="description-td">57</td>
                <td class="description-td">5</td>
                <td class="description-td">40</td>
                <td class="description-td">172</td>
                <td class="description-td">24</td>
                <td class="description-td">12</td>
                <td class="description-td">113</td>
                <td class="description-td">43</td>
                <td class="description-td">6</td>
                <td class="description-td">18</td>
              </tr> <tr class="description-tr"> <td class="description-td">JUL</td>
                <td class="description-td">M</td>
                <td class="description-td">82%</td>
                <td class="description-td">7</td>
                <td class="description-td">11</td>
                <td class="description-td">3</td>
                <td class="description-td">41</td>
                <td class="description-td">9</td>
                <td class="description-td">7</td>
                <td class="description-td">23</td>
                <td class="description-td">12</td>
                <td class="description-td">2</td>
                <td class="description-td">3</td>
              </tr> <tr class="description-tr"> <td class="description-td">KK5</td>
                <td class="description-td">M</td>
                <td class="description-td">83%</td>
                <td class="description-td">1</td>
                <td class="description-td">8</td>
                <td class="description-td">27</td>
                <td class="description-td">319</td>
                <td class="description-td">38</td>
                <td class="description-td">BQL</td>
                <td class="description-td">61</td>
                <td class="description-td">17</td>
                <td class="description-td">17</td>
                <td class="description-td">42</td>
              </tr> <tr class="description-tr"> <td class="description-td">KPT</td>
                <td class="description-td">F</td>
                <td class="description-td">83%</td>
                <td class="description-td">9</td>
                <td class="description-td">12</td>
                <td class="description-td">32</td>
                <td class="description-td">248</td>
                <td class="description-td">30</td>
                <td class="description-td">55</td>
                <td class="description-td">65</td>
                <td class="description-td">26</td>
                <td class="description-td">56</td>
                <td class="description-td">32</td>
              </tr> <tr class="description-tr"> <td class="description-td">KRJ</td>
                <td class="description-td">F</td>
                <td class="description-td">76%</td>
                <td class="description-td">6</td>
                <td class="description-td">40</td>
                <td class="description-td">76</td>
                <td class="description-td">359</td>
                <td class="description-td">37</td>
                <td class="description-td">1</td>
                <td class="description-td">11</td>
                <td class="description-td">61</td>
                <td class="description-td">23</td>
                <td class="description-td">20</td>
              </tr> <tr class="description-tr"> <td class="description-td">KRM</td>
                <td class="description-td">F</td>
                <td class="description-td">78%</td>
                <td class="description-td">126</td>
                <td class="description-td">36</td>
                <td class="description-td">55</td>
                <td class="description-td">83</td>
                <td class="description-td">17</td>
                <td class="description-td">103</td>
                <td class="description-td">98</td>
                <td class="description-td">46</td>
                <td class="description-td">74</td>
                <td class="description-td">44</td>
              </tr> <tr class="description-tr"> <td class="description-td">K5E</td>
                <td class="description-td">M</td>
                <td class="description-td">73%</td>
                <td class="description-td">65</td>
                <td class="description-td">27</td>
                <td class="description-td">52</td>
                <td class="description-td">206</td>
                <td class="description-td">74</td>
                <td class="description-td">21</td>
                <td class="description-td">123</td>
                <td class="description-td">42</td>
                <td class="description-td">93</td>
                <td class="description-td">16</td>
              </tr> <tr class="description-tr"> <td class="description-td">KZO</td>
                <td class="description-td">F</td>
                <td class="description-td">82%</td>
                <td class="description-td">38</td>
                <td class="description-td">16</td>
                <td class="description-td">38</td>
                <td class="description-td">262</td>
                <td class="description-td">8</td>
                <td class="description-td">6</td>
                <td class="description-td">75</td>
                <td class="description-td">32</td>
                <td class="description-td">30</td>
                <td class="description-td">20</td>
              </tr> <tr class="description-tr"> <td class="description-td">LAE</td>
                <td class="description-td">M</td>
                <td class="description-td">76%</td>
                <td class="description-td">58</td>
                <td class="description-td">15</td>
                <td class="description-td">50</td>
                <td class="description-td">294</td>
                <td class="description-td">22</td>
                <td class="description-td">14</td>
                <td class="description-td">67</td>
                <td class="description-td">63</td>
                <td class="description-td">125</td>
                <td class="description-td">21</td>
              </tr> <tr class="description-tr"> <td class="description-td">MOF</td>
                <td class="description-td">F</td>
                <td class="description-td">91%</td>
                <td class="description-td">79</td>
                <td class="description-td">17</td>
                <td class="description-td">29</td>
                <td class="description-td">10</td>
                <td class="description-td">12</td>
                <td class="description-td">2</td>
                <td class="description-td">85</td>
                <td class="description-td">5</td>
                <td class="description-td">7</td>
                <td class="description-td">46</td>
              </tr> <tr class="description-tr"> <td class="description-td">MRS</td>
                <td class="description-td">M</td>
                <td class="description-td">72%</td>
                <td class="description-td">119</td>
                <td class="description-td">21</td>
                <td class="description-td">110</td>
                <td class="description-td">450</td>
                <td class="description-td">50</td>
                <td class="description-td">2</td>
                <td class="description-td">675</td>
                <td class="description-td">54</td>
                <td class="description-td">68</td>
                <td class="description-td">28</td>
              </tr> <tr class="description-tr"> <td class="description-td">MTR</td>
                <td class="description-td">F</td>
                <td class="description-td">69%</td>
                <td class="description-td">2</td>
                <td class="description-td">33</td>
                <td class="description-td">23</td>
                <td class="description-td">218</td>
                <td class="description-td">3</td>
                <td class="description-td">5</td>
                <td class="description-td">38</td>
                <td class="description-td">67</td>
                <td class="description-td">39</td>
                <td class="description-td">8</td>
              </tr> <tr class="description-tr"> <td class="description-td">MYO</td>
                <td class="description-td">F</td>
                <td class="description-td">94%</td>
                <td class="description-td">40</td>
                <td class="description-td">24</td>
                <td class="description-td">9</td>
                <td class="description-td">24</td>
                <td class="description-td">BQL</td>
                <td class="description-td">BQL</td>
                <td class="description-td">12</td>
                <td class="description-td">7</td>
                <td class="description-td">BQL</td>
                <td class="description-td">11</td>
              </tr> <tr class="description-tr"> <td class="description-td">NPX</td>
                <td class="description-td">F</td>
                <td class="description-td">79%</td>
                <td class="description-td">36</td>
                <td class="description-td">32</td>
                <td class="description-td">13</td>
                <td class="description-td">130</td>
                <td class="description-td">6</td>
                <td class="description-td">15</td>
                <td class="description-td">76</td>
                <td class="description-td">25</td>
                <td class="description-td">20</td>
                <td class="description-td">10</td>
              </tr> <tr class="description-tr"> <td class="description-td">NQT</td>
                <td class="description-td">M</td>
                <td class="description-td">85%</td>
                <td class="description-td">76</td>
                <td class="description-td">12</td>
                <td class="description-td">39</td>
                <td class="description-td">80</td>
                <td class="description-td">23</td>
                <td class="description-td">2</td>
                <td class="description-td">151</td>
                <td class="description-td">14</td>
                <td class="description-td">20</td>
                <td class="description-td">34</td>
              </tr> <tr class="description-tr"> <td class="description-td">OAU</td>
                <td class="description-td">F</td>
                <td class="description-td">81%</td>
                <td class="description-td">47</td>
                <td class="description-td">26</td>
                <td class="description-td">24</td>
                <td class="description-td">86</td>
                <td class="description-td">8</td>
                <td class="description-td">6</td>
                <td class="description-td">85</td>
                <td class="description-td">46</td>
                <td class="description-td">53</td>
                <td class="description-td">13</td>
              </tr> <tr class="description-tr"> <td class="description-td">OZL</td>
                <td class="description-td">M</td>
                <td class="description-td">76%</td>
                <td class="description-td">16</td>
                <td class="description-td">15</td>
                <td class="description-td">61</td>
                <td class="description-td">300</td>
                <td class="description-td">109</td>
                <td class="description-td">3</td>
                <td class="description-td">165</td>
                <td class="description-td">29</td>
                <td class="description-td">17</td>
                <td class="description-td">43</td>
              </tr> <tr class="description-tr"> <td class="description-td">PFM</td>
                <td class="description-td">F</td>
                <td class="description-td">87%</td>
                <td class="description-td">21</td>
                <td class="description-td">1</td>
                <td class="description-td">11</td>
                <td class="description-td">67</td>
                <td class="description-td">10</td>
                <td class="description-td">3</td>
                <td class="description-td">116</td>
                <td class="description-td">8</td>
                <td class="description-td">15</td>
                <td class="description-td">33</td>
              </tr> <tr class="description-tr"> <td class="description-td">PXK</td>
                <td class="description-td">M</td>
                <td class="description-td">80%</td>
                <td class="description-td">86</td>
                <td class="description-td">35</td>
                <td class="description-td">63</td>
                <td class="description-td">433</td>
                <td class="description-td">78</td>
                <td class="description-td">2</td>
                <td class="description-td">109</td>
                <td class="description-td">62</td>
                <td class="description-td">32</td>
                <td class="description-td">60</td>
              </tr> <tr class="description-tr"> <td class="description-td">QWG</td>
                <td class="description-td">F</td>
                <td class="description-td">77%</td>
                <td class="description-td">16</td>
                <td class="description-td">32</td>
                <td class="description-td">29</td>
                <td class="description-td">300</td>
                <td class="description-td">21</td>
                <td class="description-td">9</td>
                <td class="description-td">50</td>
                <td class="description-td">10</td>
                <td class="description-td">BQL</td>
                <td class="description-td">15</td>
              </tr> <tr class="description-tr"> <td class="description-td">REL</td>
                <td class="description-td">F</td>
                <td class="description-td">77%</td>
                <td class="description-td">40</td>
                <td class="description-td">20</td>
                <td class="description-td">15</td>
                <td class="description-td">109</td>
                <td class="description-td">9</td>
                <td class="description-td">65</td>
                <td class="description-td">100</td>
                <td class="description-td">33</td>
                <td class="description-td">75</td>
                <td class="description-td">10</td>
              </tr> <tr class="description-tr"> <td class="description-td">RFA</td>
                <td class="description-td">F</td>
                <td class="description-td">78%</td>
                <td class="description-td">130</td>
                <td class="description-td">42</td>
                <td class="description-td">49</td>
                <td class="description-td">444</td>
                <td class="description-td">52</td>
                <td class="description-td">6</td>
                <td class="description-td">195</td>
                <td class="description-td">30</td>
                <td class="description-td">28</td>
                <td class="description-td">17</td>
              </tr> <tr class="description-tr"> <td class="description-td">RKB</td>
                <td class="description-td">F</td>
                <td class="description-td">95%</td>
                <td class="description-td">42</td>
                <td class="description-td">16</td>
                <td class="description-td">16</td>
                <td class="description-td">100</td>
                <td class="description-td">8</td>
                <td class="description-td">3</td>
                <td class="description-td">36</td>
                <td class="description-td">17</td>
                <td class="description-td">20</td>
                <td class="description-td">19</td>
              </tr> <tr class="description-tr"> <td class="description-td">RML</td>
                <td class="description-td">F</td>
                <td class="description-td">76%</td>
                <td class="description-td">BQL</td>
                <td class="description-td">6</td>
                <td class="description-td">45</td>
                <td class="description-td">129</td>
                <td class="description-td">31</td>
                <td class="description-td">14</td>
                <td class="description-td">152</td>
                <td class="description-td">24</td>
                <td class="description-td">42</td>
                <td class="description-td">29</td>
              </tr> <tr class="description-tr"> <td class="description-td">RNG</td>
                <td class="description-td">F</td>
                <td class="description-td">91%</td>
                <td class="description-td">119</td>
                <td class="description-td">14</td>
                <td class="description-td">97</td>
                <td class="description-td">298</td>
                <td class="description-td">27</td>
                <td class="description-td">177</td>
                <td class="description-td">207</td>
                <td class="description-td">34</td>
                <td class="description-td">71</td>
                <td class="description-td">41</td>
              </tr> <tr class="description-tr"> <td class="description-td">ROE</td>
                <td class="description-td">F</td>
                <td class="description-td">82%</td>
                <td class="description-td">73</td>
                <td class="description-td">24</td>
                <td class="description-td">36</td>
                <td class="description-td">302</td>
                <td class="description-td">37</td>
                <td class="description-td">2</td>
                <td class="description-td">55</td>
                <td class="description-td">17</td>
                <td class="description-td">2</td>
                <td class="description-td">51</td>
              </tr> <tr class="description-tr"> <td class="description-td">SEO</td>
                <td class="description-td">F</td>
                <td class="description-td">72%</td>
                <td class="description-td">36</td>
                <td class="description-td">25</td>
                <td class="description-td">18</td>
                <td class="description-td">106</td>
                <td class="description-td">9</td>
                <td class="description-td">66</td>
                <td class="description-td">102</td>
                <td class="description-td">50</td>
                <td class="description-td">81</td>
                <td class="description-td">11</td>
              </tr> <tr class="description-tr"> <td class="description-td">SQJ</td>
                <td class="description-td">F</td>
                <td class="description-td">74%</td>
                <td class="description-td">115</td>
                <td class="description-td">12</td>
                <td class="description-td">100</td>
                <td class="description-td">285</td>
                <td class="description-td">19</td>
                <td class="description-td">175</td>
                <td class="description-td">210</td>
                <td class="description-td">30</td>
                <td class="description-td">81</td>
                <td class="description-td">42</td>
              </tr> <tr class="description-tr"> <td class="description-td">SRA</td>
                <td class="description-td">M</td>
                <td class="description-td">79%</td>
                <td class="description-td">50</td>
                <td class="description-td">6</td>
                <td class="description-td">71</td>
                <td class="description-td">409</td>
                <td class="description-td">84</td>
                <td class="description-td">10</td>
                <td class="description-td">23</td>
                <td class="description-td">28</td>
                <td class="description-td">18</td>
                <td class="description-td">44</td>
              </tr> <tr class="description-tr"> <td class="description-td">TPZ</td>
                <td class="description-td">F</td>
                <td class="description-td">83%</td>
                <td class="description-td">120</td>
                <td class="description-td">13</td>
                <td class="description-td">101</td>
                <td class="description-td">301</td>
                <td class="description-td">26</td>
                <td class="description-td">171</td>
                <td class="description-td">204</td>
                <td class="description-td">31</td>
                <td class="description-td">82</td>
                <td class="description-td">41</td>
              </tr> <tr class="description-tr"> <td class="description-td">TSR</td>
                <td class="description-td">F</td>
                <td class="description-td">62%</td>
                <td class="description-td">47</td>
                <td class="description-td">66</td>
                <td class="description-td">58</td>
                <td class="description-td">175</td>
                <td class="description-td">20</td>
                <td class="description-td">BQL</td>
                <td class="description-td">6</td>
                <td class="description-td">77</td>
                <td class="description-td">16</td>
                <td class="description-td">34</td>
              </tr> <tr class="description-tr"> <td class="description-td">VCM</td>
                <td class="description-td">M</td>
                <td class="description-td">82%</td>
                <td class="description-td">42</td>
                <td class="description-td">28</td>
                <td class="description-td">79</td>
                <td class="description-td">415</td>
                <td class="description-td">110</td>
                <td class="description-td">0.2</td>
                <td class="description-td">94</td>
                <td class="description-td">16</td>
                <td class="description-td">4</td>
                <td class="description-td">215</td>
              </tr> <tr class="description-tr"> <td class="description-td">VEN</td>
                <td class="description-td">F</td>
                <td class="description-td">70%</td>
                <td class="description-td">79</td>
                <td class="description-td">69</td>
                <td class="description-td">89</td>
                <td class="description-td">328</td>
                <td class="description-td">53</td>
                <td class="description-td">2</td>
                <td class="description-td">32</td>
                <td class="description-td">58</td>
                <td class="description-td">48</td>
                <td class="description-td">81</td>
              </tr> <tr class="description-tr"> <td class="description-td">VTA</td>
                <td class="description-td">M</td>
                <td class="description-td">78%</td>
                <td class="description-td">32</td>
                <td class="description-td">1</td>
                <td class="description-td">25</td>
                <td class="description-td">84</td>
                <td class="description-td">12</td>
                <td class="description-td">5</td>
                <td class="description-td">120</td>
                <td class="description-td">21</td>
                <td class="description-td">40</td>
                <td class="description-td">15</td>
              </tr> <tr class="description-tr"> <td class="description-td">WWM</td>
                <td class="description-td">M</td>
                <td class="description-td">84%</td>
                <td class="description-td">42</td>
                <td class="description-td">1</td>
                <td class="description-td">27</td>
                <td class="description-td">127</td>
                <td class="description-td">12</td>
                <td class="description-td">6</td>
                <td class="description-td">58</td>
                <td class="description-td">21</td>
                <td class="description-td">16</td>
                <td class="description-td">37</td>
              </tr> <tr class="description-tr"> <td class="description-td">ZAG</td>
                <td class="description-td">M</td>
                <td class="description-td">85%</td>
                <td class="description-td">35</td>
                <td class="description-td">28</td>
                <td class="description-td">39</td>
                <td class="description-td">96</td>
                <td class="description-td">73</td>
                <td class="description-td">1</td>
                <td class="description-td">11</td>
                <td class="description-td">42</td>
                <td class="description-td">17</td>
                <td class="description-td">18</td>
              </tr> <tr class="description-tr"> <td class="description-td">ZCR</td>
                <td class="description-td">M</td>
                <td class="description-td">80%</td>
                <td class="description-td">84</td>
                <td class="description-td">11</td>
                <td class="description-td">39</td>
                <td class="description-td">160</td>
                <td class="description-td">22</td>
                <td class="description-td">38</td>
                <td class="description-td">14</td>
                <td class="description-td">57</td>
                <td class="description-td">20</td>
                <td class="description-td">18</td>
              </tr> <tr class="description-tr"> <td class="description-td">ZIJ</td>
                <td class="description-td">M</td>
                <td class="description-td">72%</td>
                <td class="description-td">6</td>
                <td class="description-td">33</td>
                <td class="description-td">31</td>
                <td class="description-td">320</td>
                <td class="description-td">29</td>
                <td class="description-td">13</td>
                <td class="description-td">25</td>
                <td class="description-td">34</td>
                <td class="description-td">3</td>
                <td class="description-td">13</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="13" align="center" rowsep="1" class="description-td" colspan="13"> </td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="13" align="left" id="FOO-00001" class="description-td" colspan="13">BQL (Below Quantitation Limit)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="13" align="left" id="FOO-00002" class="description-td" colspan="13">TBD (To Be Determined)</td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <heading>EXAMPLE 3</heading> <heading>Characterization of Pooled Hepatocytes</heading> <p num="p-0061">Cryopreserved pooled lots of hepatocytes are prepared and analyzed for post-thaw viability and enzyme function. The following metabolic activities are evaluated: COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, TOLB, PHEN, and CZX.</p>
    <p num="p-0062">Six lots of pooled hepatocytes, comprising either five-donor pools or ten-donor pools, are prepared as described above. Hepatocytes are harvested from individual donors and then cryopreserved as individual lots using liquid nitrogen as freezing agent. Cryopreservation is accomplished by suspending the hepatocytes into freezer-safe vials containing a medium having approximately 10% DMSO and approximately 90% Cryopreservation Medium. The dispensed hepatocytes are then frozen in a controlled rate freezer until a final temperature of approximately −80° C. is reached.</p>
    <p num="p-0063">To form the pooled hepatocyte preparations, individual lots are thawed, and the viable cells are isolated by percoll gradient centrifugation. Vials of individual donor cryopreserved hepatocytes were thawed in a 37° C. waterbath (perhaps it would be better to give a range such as 30-40° C. waterbath?) for 60-90 seconds. The thawed cells are decanted into 37° C. media containing 30% Isotonic Percoll and 70% CP-2 media. The cell suspension is centrifuged at 100 g for 20 minutes. The viable cells are recovered in cryopreservation media and counted. The viable cells are diluted to 20 million cells per mL. A second solution containing 20% DMSO and 80% cryopreservation media (equal volume to the cell suspension listed above) is prepared. The 20% DMSO and 80% cryopreservation media is slowly added to the cells suspension mixture. The addition takes 5-10 minutes. The resulting mixture is 10% DMSO, 90% cryopreservation media with cells at 10 million cells per mL. This solution is aliquoted into cryovials at 1.0 mL per vial. The cells are then cryopreserved. Viable cells from individual lots are then pooled to form pooled hepatocyte preparations whose cells have functional assay values within desired ranges.</p>
    <p num="p-0064">The pooled lots are then cryopreserved. Table IV below shows the results of the post-thaw viability (“% V”) and enzyme function analysis of the pooled lots. As indicated in Table III, pools had an average viability of 79% (S.D. ±6%).</p>
    <p num="p-0065">
      <tables id="TABLE-US-00004" num="00004"> <table frame="none" colsep="0" rowsep="0" pgwide="1" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="308pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE IV</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Summary of Pooled Hepatocyte Lot Data</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="12"> <colspec colname="1" colwidth="28pt" align="left"> </colspec> <colspec colname="2" colwidth="21pt" align="center"> </colspec> <colspec colname="3" colwidth="28pt" align="center"> </colspec> <colspec colname="4" colwidth="21pt" align="center"> </colspec> <colspec colname="5" colwidth="28pt" align="center"> </colspec> <colspec colname="6" colwidth="28pt" align="center"> </colspec> <colspec colname="7" colwidth="28pt" align="center"> </colspec> <colspec colname="8" colwidth="28pt" align="center"> </colspec> <colspec colname="9" colwidth="21pt" align="center"> </colspec> <colspec colname="10" colwidth="28pt" align="center"> </colspec> <colspec colname="11" colwidth="28pt" align="center"> </colspec> <colspec colname="12" colwidth="21pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Pool</td>
                <td class="description-td">% V</td>
                <td class="description-td">COUM</td>
                <td class="description-td">DEX</td>
                <td class="description-td">ECOD</td>
                <td class="description-td">7-HCG</td>
                <td class="description-td">7-HCS</td>
                <td class="description-td">MEPH</td>
                <td class="description-td">TEST</td>
                <td class="description-td">TOLB</td>
                <td class="description-td">PHEN</td>
                <td class="description-td">CZX</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="12" align="center" rowsep="1" class="description-td" colspan="12"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="12"> <colspec colname="1" colwidth="28pt" align="left"> </colspec> <colspec colname="2" colwidth="21pt" align="center"> </colspec> <colspec colname="3" colwidth="28pt" align="center"> </colspec> <colspec colname="4" colwidth="21pt" align="center"> </colspec> <colspec colname="5" colwidth="28pt" align="center"> </colspec> <colspec colname="6" colwidth="28pt" align="center"> </colspec> <colspec colname="7" colwidth="28pt" align="center"> </colspec> <colspec colname="8" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="9" colwidth="21pt" align="char" char="."> </colspec> <colspec colname="10" colwidth="28pt" align="center"> </colspec> <colspec colname="11" colwidth="28pt" align="center"> </colspec> <colspec colname="12" colwidth="21pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">MJI<sup>a</sup> </td>
                <td class="description-td">89</td>
                <td class="description-td">63</td>
                <td class="description-td">28</td>
                <td class="description-td">66</td>
                <td class="description-td">301</td>
                <td class="description-td">44</td>
                <td class="description-td">12</td>
                <td class="description-td">70</td>
                <td class="description-td">61</td>
                <td class="description-td">50</td>
                <td class="description-td">62</td>
              </tr> <tr class="description-tr"> <td class="description-td">YDJ<sup>a</sup> </td>
                <td class="description-td">72</td>
                <td class="description-td">66</td>
                <td class="description-td">30</td>
                <td class="description-td">80</td>
                <td class="description-td">470</td>
                <td class="description-td">41</td>
                <td class="description-td">1</td>
                <td class="description-td">165</td>
                <td class="description-td">31</td>
                <td class="description-td">27</td>
                <td class="description-td">71</td>
              </tr> <tr class="description-tr"> <td class="description-td">APO<sup>b</sup> </td>
                <td class="description-td">79</td>
                <td class="description-td">79</td>
                <td class="description-td">21</td>
                <td class="description-td">55</td>
                <td class="description-td">276</td>
                <td class="description-td">43</td>
                <td class="description-td">2</td>
                <td class="description-td">112</td>
                <td class="description-td">22</td>
                <td class="description-td">26</td>
                <td class="description-td">30</td>
              </tr> <tr class="description-tr"> <td class="description-td">HMB<sup>b</sup> </td>
                <td class="description-td">76</td>
                <td class="description-td">61</td>
                <td class="description-td">18</td>
                <td class="description-td">70</td>
                <td class="description-td">231</td>
                <td class="description-td">46</td>
                <td class="description-td">3</td>
                <td class="description-td">151</td>
                <td class="description-td">23</td>
                <td class="description-td">20</td>
                <td class="description-td">83</td>
              </tr> <tr class="description-tr"> <td class="description-td">IJU<sup>b</sup> </td>
                <td class="description-td">75</td>
                <td class="description-td">32</td>
                <td class="description-td">19</td>
                <td class="description-td">35</td>
                <td class="description-td">232</td>
                <td class="description-td">44</td>
                <td class="description-td">2</td>
                <td class="description-td">124</td>
                <td class="description-td">32</td>
                <td class="description-td">11</td>
                <td class="description-td">42</td>
              </tr> <tr class="description-tr"> <td class="description-td">RKS<sup>b</sup> </td>
                <td class="description-td">81</td>
                <td class="description-td">84</td>
                <td class="description-td">20</td>
                <td class="description-td">73</td>
                <td class="description-td">336</td>
                <td class="description-td">53</td>
                <td class="description-td">2</td>
                <td class="description-td">131</td>
                <td class="description-td">28</td>
                <td class="description-td">23</td>
                <td class="description-td">55</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="12" align="center" rowsep="1" class="description-td" colspan="12"> </td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="12" align="left" id="FOO-00003" class="description-td" colspan="12"> <sup>a</sup>5-donor lots</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="12" align="left" id="FOO-00004" class="description-td" colspan="12"> <sup>b</sup>10-donor lots</td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0066">For comparison, Table V below shows summary data for a post-thaw viability and enzyme function analysis of eighty-one individual lots that are cryopreserved (i.e., subjected to one cycle of cryopreservation). This data confirms that the lot-to-lot variability of enzyme function found in individual hepatocyte sources is very high. The data confirms the desirability of employing pooled hepatocyte preparations for providing cryopreserved cells that approximate the enzyme function of “average” hepatocytes for a wide variety of enzymes.</p>
    <p num="p-0067">
      <tables id="TABLE-US-00005" num="00005"> <table frame="none" colsep="0" rowsep="0" pgwide="1" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="301pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE V</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Summary of Pooled Hepatocyte Lot Data</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="12"> <colspec colname="offset" colwidth="21pt" align="left"> </colspec> <colspec colname="1" colwidth="21pt" align="center"> </colspec> <colspec colname="2" colwidth="28pt" align="center"> </colspec> <colspec colname="3" colwidth="21pt" align="center"> </colspec> <colspec colname="4" colwidth="28pt" align="center"> </colspec> <colspec colname="5" colwidth="28pt" align="center"> </colspec> <colspec colname="6" colwidth="28pt" align="center"> </colspec> <colspec colname="7" colwidth="28pt" align="center"> </colspec> <colspec colname="8" colwidth="21pt" align="center"> </colspec> <colspec colname="9" colwidth="28pt" align="center"> </colspec> <colspec colname="10" colwidth="28pt" align="center"> </colspec> <colspec colname="11" colwidth="21pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">% V</td>
                <td class="description-td">COUM</td>
                <td class="description-td">DEX</td>
                <td class="description-td">ECOD</td>
                <td class="description-td">7-HCG</td>
                <td class="description-td">7-HCS</td>
                <td class="description-td">MEPH</td>
                <td class="description-td">TEST</td>
                <td class="description-td">TOLB</td>
                <td class="description-td">PHEN</td>
                <td class="description-td">CZX</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="11" align="center" rowsep="1" class="description-td" colspan="12"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="12"> <colspec colname="1" colwidth="21pt" align="left"> </colspec> <colspec colname="2" colwidth="21pt" align="center"> </colspec> <colspec colname="3" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="4" colwidth="21pt" align="char" char="."> </colspec> <colspec colname="5" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="6" colwidth="28pt" align="center"> </colspec> <colspec colname="7" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="8" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="9" colwidth="21pt" align="char" char="."> </colspec> <colspec colname="10" colwidth="28pt" align="center"> </colspec> <colspec colname="11" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="12" colwidth="21pt" align="char" char="."> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Avg</td>
                <td class="description-td">79</td>
                <td class="description-td">37</td>
                <td class="description-td">17</td>
                <td class="description-td">51</td>
                <td class="description-td">276</td>
                <td class="description-td">27</td>
                <td class="description-td">8</td>
                <td class="description-td">35</td>
                <td class="description-td">35</td>
                <td class="description-td">15</td>
                <td class="description-td">19</td>
              </tr> <tr class="description-tr"> <td class="description-td">High</td>
                <td class="description-td">95</td>
                <td class="description-td">134</td>
                <td class="description-td">69</td>
                <td class="description-td">110</td>
                <td class="description-td">471</td>
                <td class="description-td">110</td>
                <td class="description-td">177</td>
                <td class="description-td">675</td>
                <td class="description-td">82</td>
                <td class="description-td">125</td>
                <td class="description-td">215</td>
              </tr> <tr class="description-tr"> <td class="description-td">Low</td>
                <td class="description-td">62</td>
                <td class="description-td">6</td>
                <td class="description-td">1</td>
                <td class="description-td">31</td>
                <td class="description-td">231</td>
                <td class="description-td">24</td>
                <td class="description-td">2</td>
                <td class="description-td">25</td>
                <td class="description-td">34</td>
                <td class="description-td">3</td>
                <td class="description-td">13</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="12" align="center" rowsep="1" class="description-td" colspan="12"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <heading>EXAMPLE 3</heading> <heading>Characterization of the Viability of Pooled Hepatocytes After Thawing</heading> <p num="p-0068">A common use of for cryopreserved hepatocytes is to thaw the hepatocytes and then incubate them with various xenobiotics. For this purpose, it is preferred that the hepatocytes maintain their viability for at least several hours. To examine the post-thaw viability over time for one lot of pooled cryopreserved hepatocytes, the cells were thawed, aliquoted into the wells of a 12-well plate, and incubated at 37° C. with 5% CO<sub>2</sub>. The viability of the hepatocytes is then measured at time-points for up to six hours. Table VI shows the results of this analysis, wherein, at six hours, 39% of the hepatocytes remained viable</p>
    <p num="p-0069">
      <tables id="TABLE-US-00006" num="00006"> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE VI</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Post-Thaw Viability Analysis of a Pooled Hepatocyte Lot</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="42pt" align="left"> </colspec> <colspec colname="1" colwidth="42pt" align="center"> </colspec> <colspec colname="2" colwidth="133pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Timepoint</td>
                <td class="description-td">% Viability <sup>a</sup> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">T = 0</td>
                <td class="description-td">88%</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">0.5 hrs</td>
                <td class="description-td">79%</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">1.0 hrs</td>
                <td class="description-td">84%</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">2.0 hrs</td>
                <td class="description-td">79%</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">3.0 hrs</td>
                <td class="description-td">73%</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">4.0 hrs</td>
                <td class="description-td">67%</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">6.0 hrs</td>
                <td class="description-td">69%</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="left" id="FOO-00005" class="description-td" colspan="3"> <sup>a </sup>viability determined by Trypan Blue</td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0070">All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.</p>
    <p num="p-0071">While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5795711">US5795711</a></td><td class="patent-data-table-td patent-date-value">Apr 4, 1996</td><td class="patent-data-table-td patent-date-value">Aug 18, 1998</td><td class="patent-data-table-td ">Circe Biomedical, Inc.</td><td class="patent-data-table-td ">Artificial liver and cells with metabolic activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5895745">US5895745</a></td><td class="patent-data-table-td patent-date-value">Sep 25, 1996</td><td class="patent-data-table-td patent-date-value">Apr 20, 1999</td><td class="patent-data-table-td ">W.R. Grace &amp; Co.-Conn.</td><td class="patent-data-table-td ">Method of thawing cryopreserved cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6136525">US6136525</a></td><td class="patent-data-table-td patent-date-value">Aug 2, 1999</td><td class="patent-data-table-td patent-date-value">Oct 24, 2000</td><td class="patent-data-table-td ">Circe Biomedical, Inc.</td><td class="patent-data-table-td ">Dispensing hepatocytes into freezing containers, freezing from between minus 50 to minus 90 degrees celsius in control rate freezer using specified program, storing containers in liquid or vapor nitrogen, thawing and removing cryoprotectant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6759245">US6759245</a></td><td class="patent-data-table-td patent-date-value">Jun 21, 2000</td><td class="patent-data-table-td patent-date-value">Jul 6, 2004</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Has modular cell culturing devices with flat-plate modules, flow of liquid medium and oxygenated fluid are separated by a gas-permeable, liquid-impermeable membrane, and the cells are grown attached to the liquid side of the membrane</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20020039786">US20020039786</a></td><td class="patent-data-table-td patent-date-value">Jan 19, 2001</td><td class="patent-data-table-td patent-date-value">Apr 4, 2002</td><td class="patent-data-table-td ">Reid Lola M.</td><td class="patent-data-table-td ">Generating progenitor cells; provide cells for organ grafting, propagate cells, recover cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20030134418">US20030134418</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2002</td><td class="patent-data-table-td patent-date-value">Jul 17, 2003</td><td class="patent-data-table-td ">Hokkaido Technology Licensing Office Co, Ltd.</td><td class="patent-data-table-td ">Separating then enriching culture with nonparenchymal cells supplemented with nicotinamide; cell proliferation/detoxification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0834252B1?cl=en">EP0834252B1</a></td><td class="patent-data-table-td patent-date-value">Sep 24, 1997</td><td class="patent-data-table-td patent-date-value">Dec 10, 2003</td><td class="patent-data-table-td ">Circe Biomedical, Inc.</td><td class="patent-data-table-td ">Method of thawing cryopreserved cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1992012722A1?cl=en">WO1992012722A1</a></td><td class="patent-data-table-td patent-date-value">Jan 17, 1991</td><td class="patent-data-table-td patent-date-value">Jul 18, 1992</td><td class="patent-data-table-td ">Univ California</td><td class="patent-data-table-td ">Antifreeze glycopeptide compositions to protect cells and tissues during freezing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2001053462A1?cl=en">WO2001053462A1</a></td><td class="patent-data-table-td patent-date-value">Jan 19, 2001</td><td class="patent-data-table-td patent-date-value">Jul 26, 2001</td><td class="patent-data-table-td ">Univ North Carolina</td><td class="patent-data-table-td ">Liver tissue source</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003105663A2?cl=en">WO2003105663A2</a></td><td class="patent-data-table-td patent-date-value">Jun 13, 2003</td><td class="patent-data-table-td patent-date-value">Dec 24, 2003</td><td class="patent-data-table-td ">Stelsys Llc</td><td class="patent-data-table-td ">Liver assist system based on hollow fiber cartridges or rotating bioreactor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004009766A2?cl=en">WO2004009766A2</a></td><td class="patent-data-table-td patent-date-value">Jul 17, 2003</td><td class="patent-data-table-td patent-date-value">Jan 29, 2004</td><td class="patent-data-table-td ">Andrew T Bruce</td><td class="patent-data-table-td ">Method of obtaining viable human liver cells, including hepatic stem/progenitor cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005000376A2?cl=en">WO2005000376A2</a></td><td class="patent-data-table-td patent-date-value">May 19, 2004</td><td class="patent-data-table-td patent-date-value">Jan 6, 2005</td><td class="patent-data-table-td ">Hepahope Inc</td><td class="patent-data-table-td ">Bio-artificial liver system</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Adams, R.M. et al. (1995) "<a href='http://scholar.google.com/scholar?q="Effective+Cryopreservation+And+Long-Term+Storage+Of+Primary+Human+Hepatocytes+With+Recovery+Of+Viability%2C+Differentiation%2C+And+Replicative+Potential%2C"'>Effective Cryopreservation And Long-Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential,</a>" Cell Transplant. 4(6):579-586.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Alexandre, E. et al. (2002) "<a href='http://scholar.google.com/scholar?q="Cryopreservation+Of+Adult+Human+Hepatocytes+Obtained+From+Resected+Liver+Biopsies%2C"'>Cryopreservation Of Adult Human Hepatocytes Obtained From Resected Liver Biopsies,</a>" Cryobiology 44:103-113.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Anand, A.C. (1996) "<a href='http://scholar.google.com/scholar?q="Bioartificial+Livers%3A+The+State+Of+The+Art%2C"'>Bioartificial Livers: The State Of The Art,</a>" Trop Gastroenterol. 17(4):197-198, 202-211.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Arikura et al., UW solution: a promising tool for cryopreservation of primarily isolated rat hepatocytes, 9 J. Hepatobiliary Pancreat. Surg. 742-749 (2002).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Berry, M.N. et al. (1992) "<a href='http://scholar.google.com/scholar?q="Techniques+for+Pharmacological+And+Toxicological+Studies+With+Isolated+Hepatocyte+Suspensions%2C"'>Techniques for Pharmacological And Toxicological Studies With Isolated Hepatocyte Suspensions,</a>" Life Sci. 51(1):1-16.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Burlina, A.B. (2004) "<a href='http://scholar.google.com/scholar?q="Hepatocyte+Transplantation+For+Inborn+Errors+Of+Metabolism%2C"'>Hepatocyte Transplantation For Inborn Errors Of Metabolism,</a>" J. Inherit. Metab. Dis. 27(3):373-83.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chan, C. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Hepatic+Tissue+Engineering+For+Adjunct+And+Temporary+Liver+Support%3A+Critical+Technologies%2C"'>Hepatic Tissue Engineering For Adjunct And Temporary Liver Support: Critical Technologies,</a>" Liver Transpl. 10(11):1331-1342.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chesne, C. et al. (1993) "<a href='http://scholar.google.com/scholar?q="Viability+And+Function+In+Primary+Culture+Of+Adult+Hepatocytes+From+Various+Animal+Species+And+Human+Beings+After+Cryopreservation%2C"'>Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation,</a>" Hepatology 18(2):406-414.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Coundouris, J.A. et al. (1993) "<a href='http://scholar.google.com/scholar?q="Cryopreservation+Of+Human+Adult+Hepatocytes+For+Use+In+Drug+Metabolism+And+Toxicity+Studies%2C"'>Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies,</a>" Xenobiotica. 23(12):1399-1409.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Diener, B. et al. (1993) "<a href='http://scholar.google.com/scholar?q="A+Method+For+The+Cryopreservation+Of+Liver+Parenchymal+Cells+For+Studies+Of+Xenobiotics%2C"'>A Method For The Cryopreservation Of Liver Parenchymal Cells For Studies Of Xenobiotics,</a>" Cryobiology 30(2):116-127.</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dou, M. et al. (1992) "<a href='http://scholar.google.com/scholar?q="Thawed+Human+Hepatocytes+In+Primary+Culture%2C"'>Thawed Human Hepatocytes In Primary Culture,</a>" Cryobiology 29(4):454-69.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fox, I.J. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Hepatocyte+Transplantation%2C"'>Hepatocyte Transplantation,</a>" Am. J. Transplant.4 Suppl. 6:7-13.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fukuda, J. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Hepatocyte+Organoid+Culture+In+Elliptic+Hollow+Fibers+To+Develop+A+Hybrid+Artificial+Liver%2C"'>Hepatocyte Organoid Culture In Elliptic Hollow Fibers To Develop A Hybrid Artificial Liver,</a>" Int J Artif Organs. 27(12):1091-1099.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gan, J.H. et al. (2005) "<a href='http://scholar.google.com/scholar?q="Hybrid+Artificial+Liver+Support+System+For+Treatment+of+Severe+Liver+Failure%2C"'>Hybrid Artificial Liver Support System For Treatment of Severe Liver Failure,</a>" World J Gastroenterol. 11(6):890-894.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gomez-Lechon, M.J. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Human+Hepatocytes+In+Primary+Culture%3A+The+Choice+To+Investigate+Drug+Metabolism+in+Man%2C"'>Human Hepatocytes In Primary Culture: The Choice To Investigate Drug Metabolism in Man,</a>" Curr Drug Metab. 5(5):443-462.</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Guillouzo, A. et al. (1986) "<a href='http://scholar.google.com/scholar?q="Isolated+and+Cultured+Hepatocytes%2C"'>Isolated and Cultured Hepatocytes,</a>" Paris: les Editions INSERM and London: John Libbey Eurotext).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hengstler et al., Drug Metab. Rev., 2000, 32: 81-118, Abstract.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hewitt, N.J. et al. (2004) Cryopreserved Rat, Dog and Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures, Hum Exp Toxicol. 23(6)307-316.</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Horslen, S.P. (2004) "<a href='http://scholar.google.com/scholar?q="Hepatocyte+Transplantation%2C"'>Hepatocyte Transplantation,</a>" Transplantation 77(10):1481-1486.</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Houle, r. et al. (2003) "<a href='http://scholar.google.com/scholar?q="Retention+Of+Transporter+Activities+in+Cryopreserved%2C+Isolated+Rat+Hepatocytes%2C"'>Retention Of Transporter Activities in Cryopreserved, Isolated Rat Hepatocytes,</a>" Drug Metab. Disposit. 31(4):447-451.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kasai, s. et al. (1993) "<a href='http://scholar.google.com/scholar?q="Large+Scale+Cryopreservation+of+Isolated+Dog+Hepatocytes%2C"'>Large Scale Cryopreservation of Isolated Dog Hepatocytes,</a>" Cryobiology 30:1-11.</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lawrence, J.N. et al. (1991) "<a href='http://scholar.google.com/scholar?q="Development+Of+An+Optimal+Method+For+The+Cryopreservation+Of+Hepatocytes+And+Their+Subsequent+Monolayer+Culture.+Toxicology+In+Vitro%2C"'>Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture. Toxicology In Vitro,</a>" 5(1):39-51.</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lee, S. W. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Hepatocyte+Transplantation%3A+State+Of+The+Art+And+Strategies+For+Overcoming+Existing+Hurdles%2C"'>Hepatocyte Transplantation: State Of The Art And Strategies For Overcoming Existing Hurdles,</a>" Ann. Hepatol. 3(2):48-53.</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lemaigre, F. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Liver+Development+Update%3A+New+Embryo+Models%2C+Cell+Lineage+Control%2C+And+Morphogenesis%2C"'>Liver Development Update: New Embryo Models, Cell Lineage Control, And Morphogenesis,</a>" Curr Opin Genet Dev. 14(5):582-590.</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Li et al., Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics . . . , 121 Chemico-Biological Interactions 117-123 (1999).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Li, A.P. et al. (1992) "<a href='http://scholar.google.com/scholar?q="Isolation+And+Culturing+Of+Hepatocytes+From+Human+Liver%2C"'>Isolation And Culturing Of Hepatocytes From Human Liver,</a>" J. Tissue Cult. Meth. 14:139-146.</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Li, A.P. et al. (1999) "<a href='http://scholar.google.com/scholar?q="Cryopreserved+Human+Hepatocytes%3A+Characterization+Of+Drug-Metabolizing+Enzyme+Activities+And+Applications+In+Higher+Throughput+Screening+Assays+For+Hepatotoxicity%2C+Metabolic+Stability%2C+And+Drug-Drug+Interaction+Potential%2C"'>Cryopreserved Human Hepatocytes: Characterization Of Drug-Metabolizing Enzyme Activities And Applications In Higher Throughput Screening Assays For Hepatotoxicity, Metabolic Stability, And Drug-Drug Interaction Potential,</a>" Chem Biol Interact. 121(1):17-35.</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Li, A.P. et al. (1999) "<a href='http://scholar.google.com/scholar?q="Present+Status+Of+The+Application+Of+Cryopreserved+Hepatocytes+In+The+Evaluation+Of+Xenobiotics%3A+Consensus+Of+An+International+Expert+Panel%2C"'>Present Status Of The Application Of Cryopreserved Hepatocytes In The Evaluation Of Xenobiotics: Consensus Of An International Expert Panel,</a>" Chem Biol Interact. 121(I):117-123.</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Li, Overview: hepatocytes and cryopreservation-a personal historical perspective, 121 Chemico-Biological Interactions 1-5 (1999).</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lloyd, T.D.R. et al. (2003) Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking, Cell and Tissue Culture Banking 4:3-15.</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Loretz, L.J. et al. (1989) "<a href='http://scholar.google.com/scholar?q="Optimization+Of+Cryopreservation+Procedures+For+Rat+And+Human+Hepatocytes%2C"'>Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes,</a>" Xenobiotica. 19(5):489-498.</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Madan, A. et al. (1999)"<a href='http://scholar.google.com/scholar?q="Effect+of+Cryopreservation+on+Cytochrome+P-450+Enzyme+Induction+in+Cultured+Rat+Hepatocytes%2C"'>Effect of Cryopreservation on Cytochrome P-450 Enzyme Induction in Cultured Rat Hepatocytes,</a>" Drug Metab. Dispos. 27(3):327-335.</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Marsh et al., Hypothermic Preservation of Hepatocytes III Effects of Resuspension Media on Viability after up to 7 Days of Storage, 13(3) Hepatology 500-508 (1991).</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Meng, Q. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Hepatocyte+Culture+In+Bioartificial+Livers+With+Different+Membrane+Characteristics%2C"'>Hepatocyte Culture In Bioartificial Livers With Different Membrane Characteristics,</a>" Biotechnol Lett. 26(18):1407-1412.</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Morsiani et al., (1995) "<a href='http://scholar.google.com/scholar?q="Automated+Liver+Cell+Processing+Facilitates+Large+Scale+Isolation+And+Purification+Of+Porcine+Hepatocytes%2C"'>Automated Liver Cell Processing Facilitates Large Scale Isolation And Purification Of Porcine Hepatocytes,</a>" ASAIO Journal 41:155-161.</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nanji, A.A. (2004) "<a href='http://scholar.google.com/scholar?q="Animal+Models+Of+Nonalcoholic+Fatty+Liver+Disease+And+Steatohepatitis%2C"'>Animal Models Of Nonalcoholic Fatty Liver Disease And Steatohepatitis,</a>" Clin Liver Dis. 8(3):559-574.</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Novicki, D.L. et al. (1982) "<a href='http://scholar.google.com/scholar?q="Cryopreservation+Of+Isolated+Rat+Hepatocytes%2C"'>Cryopreservation Of Isolated Rat Hepatocytes,</a>" In Vitro. 18(4):393-399.</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">O'Brien, Z.Z. et al. (undated) "<a href='http://scholar.google.com/scholar?q="The+Construction+Of+A+Representative+Human+Cryopreserved+Hepatocyte+Pool+For+Metabolism+Study%2C"'>The Construction Of A Representative Human Cryopreserved Hepatocyte Pool For Metabolism Study,</a>".</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Oehninger et al., Mol Cell Endocrinol, 2000, 169: 3-10.</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ostrowska et al., Cell and Tissue Banking, 2000, 1: 55-68.</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ponsoda, X. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Drug+Metabolism+By+Cultured+Human+Hepatocytes%3A+How+Far+Are+We+From+The+In+Vivo+Reality%3F"'>Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?</a>" Altern Lab Anim. 32(2): 101-110.</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Postic, C. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Role+Of+The+Liver+In+The+Control+Of+Carbohydrate+And+Lipid+Homeostasis%2C"'>Role Of The Liver In The Control Of Carbohydrate And Lipid Homeostasis,</a>" Diabetes Metab. 30(5):398-408.</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Roymans, D. et al. (2004) "<a href='http://scholar.google.com/scholar?q="Determination+Of+Cytochrome+P450+1A2+And+Cytochrome+P4503a4+Induction+In+Cryopreserved+Human+Hepatocytes%2C"'>Determination Of Cytochrome P450 1A2 And Cytochrome P4503a4 Induction In Cryopreserved Human Hepatocytes,</a>" Biochem Pharmacol. 67(3):427-437.</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ruegg, C.E. et al. (1997) "<a href='http://scholar.google.com/scholar?q="Cytochrome-P450+Induction+and+Conjugated+Metabolism+In+Primary+Human+Hepastocytes+After+Cryopreservation%2C"'>Cytochrome-P450 Induction and Conjugated Metabolism In Primary Human Hepastocytes After Cryopreservation,</a>" In Vitro Toxicol. 10:217-222.</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Seglen, P.O. (1976) "<a href='http://scholar.google.com/scholar?q="Preparation+Of+Isolated+Rat+Liver+Cells%2C"'>Preparation Of Isolated Rat Liver Cells,</a>" Meth. Cell Biol. 13:29-83).</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sekido, H. el al. (2004) "<a href='http://scholar.google.com/scholar?q="Usefulness+Of+Artificial+Liver+Support+For+Pretransplant+Patients+With+Fulminant+Hepatic+Failure%2C"'>Usefulness Of Artificial Liver Support For Pretransplant Patients With Fulminant Hepatic Failure,</a>" Transplant Proc. 36(8):2355-2356.</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Shaddock, J,G. et al. (1993) "<a href='http://scholar.google.com/scholar?q="Cryopreservation+And+Long-Term+Storage+Of+Primary+Rat+Hepatocytes%3A+Effects+On+Substrate-Specific+Cytochrome+P450-Dependent+Activities+And+Unscheduled+DNA+Synthesis%2C"'>Cryopreservation And Long-Term Storage Of Primary Rat Hepatocytes: Effects On Substrate-Specific Cytochrome P450-Dependent Activities And Unscheduled DNA Synthesis,</a>" Cell Biol Toxicol. 9(4):345-357.</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Shibata et al., Drug Metabolism and Disposition, 2002, 30: 892-896.</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Silva, J.M. et al. (1999) "<a href='http://scholar.google.com/scholar?q="Induction+Of+Cytochrome-P450+In+Cryopreserved+Rat+And+Human+Hepatocytes%2C"'>Induction Of Cytochrome-P450 In Cryopreserved Rat And Human Hepatocytes,</a>" Chem-Biol Interact 121:49-63.</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Smrzova et al., Optimisation of Porcine Hepatocyte Cryopreservation by Comparison of Viability and Enzymatic Activity of Fresh and Cryopreserved Cells, 70 Acta Vet. Bmo. 141-147 (2001).</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sun, E.L. et al. (1990) "<a href='http://scholar.google.com/scholar?q="Cryopreservation+Of+Cynomologus+Monkey+%28Macaca+fascicularis%29+Hepatocytes+For+Subsequent+Culture+And+Protein+Synthesis+Studies%2C"'>Cryopreservation Of Cynomologus Monkey (Macaca fascicularis) Hepatocytes For Subsequent Culture And Protein Synthesis Studies,</a>" In vitro Cell Development and Biology 25:147-150.</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Utesch, D. et al. (1992) "<a href='http://scholar.google.com/scholar?q="Characterization+Of+Cryopreserved+Rat+Liver+Parenchymal+Cells+By+Metabolism+Of+Diagnostic+Substrates+And+Activities+Of+Related+Enzymes%2C"'>Characterization Of Cryopreserved Rat Liver Parenchymal Cells By Metabolism Of Diagnostic Substrates And Activities Of Related Enzymes,</a>" Biochemical Pharmacology 44:309-315.</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Vincent et al., Adjustment of the Osmolality of Percoll for the Isopycnic Separation of Cells and Cell Organelles, 141 Analytical Biochemistry 322-328 (1984).</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Zaleski, J. et al. (1993) "<a href='http://scholar.google.com/scholar?q="Preservation+Of+The+Rate+And+Profile+Of+Xenobiotic+Metabolism+In+Rat+Hepatocytes+Stored+In+Liquid+Nitrogen%2C"'>Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen,</a>" Biochem Pharmacol. 46(1):111-116.</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Zhang, J.G. et al. (undated) "<a href='http://scholar.google.com/scholar?q="Validation+of+Pooled+Cryopreserved+Human+Hepatocytes+as+a+Model+for+Metabolism+Studies"'>Validation of Pooled Cryopreserved Human Hepatocytes as a Model for Metabolism Studies</a>" www. Bdbiosciences.com.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8425662">US8425662</a></td><td class="patent-data-table-td patent-date-value">Apr 1, 2011</td><td class="patent-data-table-td patent-date-value">Apr 23, 2013</td><td class="patent-data-table-td ">Battelle Memorial Institute</td><td class="patent-data-table-td ">Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8513015">US8513015</a></td><td class="patent-data-table-td patent-date-value">May 19, 2011</td><td class="patent-data-table-td patent-date-value">Aug 20, 2013</td><td class="patent-data-table-td ">Corning Incorporated</td><td class="patent-data-table-td ">Laminin-entactin complex and cell culture article and methods thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1891208A2?cl=en">EP1891208A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by third party"> †</span></td><td class="patent-data-table-td patent-date-value">Mar 30, 2006</td><td class="patent-data-table-td patent-date-value">Feb 27, 2008</td><td class="patent-data-table-td ">In Vitro Technologies, Inc.</td><td class="patent-data-table-td ">Novel cellular compositions and methods for their preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012018955A2?cl=en">WO2012018955A2</a></td><td class="patent-data-table-td patent-date-value">Aug 3, 2011</td><td class="patent-data-table-td patent-date-value">Feb 9, 2012</td><td class="patent-data-table-td ">Life Technologies Corporation</td><td class="patent-data-table-td ">Cellular compositions and methods for their preparation and use</td></tr></table><div class="patent-section-footer">† Cited by third party</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S001100">435/1.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S001300">435/1.3</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S370000">435/370</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S374000">435/374</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S375000">435/375</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A01N0001020000">A01N1/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0005000000">C12N5/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A01N0001000000">A01N1/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0005071000">C12N5/071</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=-FvnBQABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N5/067">C12N5/067</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C12N5/06B14</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Jun 23, 2014</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE OF SECURITY INTEREST;ASSIGNOR:BROWN BROTHERS HARRIMAN &amp; CO., AS ADMINISTRATIVE AGENT;REEL/FRAME:033217/0051</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CELSIS IN VITRO, INC., MARYLAND</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20130628</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 10, 2014</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:CELSIS IN VITRO, INC.;REEL/FRAME:033114/0433</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20130705</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">IN VITRO, INC., MARYLAND</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 9, 2014</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20140609</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT, ILLINO</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF SECURITY INTEREST IN PATENTS;ASSIGNOR:ABACUS FINANCE GROUP, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:033106/0921</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 2, 2013</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ABACUS FINANCE GROUP, LLC, AS AGENT, NEW YORK</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20130628</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:CELSIS IN VITRO, INC.;REEL/FRAME:030745/0323</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 19, 2013</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 21, 2013</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20130313</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:CELSIS IN VITRO, INC.;REEL/FRAME:030055/0686</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BROWN BROTHERS HARRIMAN &amp; CO., AS ADMINISTRATIVE A</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 11, 2013</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CELSIS IN VITRO, INC., MARYLAND</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20130308</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE BY SECURED PARTY;ASSIGNOR:KBC BANK NV;REEL/FRAME:029959/0326</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 2, 2012</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20120816</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 28, 2012</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 1-9 AND 11 IS CONFIRMED. CLAIM 10 IS CANCELLED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 1, 2011</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20101008</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 28, 2010</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20101013</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 15, 2010</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 27, 2010</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">KBC BANK NV,UNITED KINGDOM</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:CELSIS IN VITRO, INC.;US-ASSIGNMENT DATABASE UPDATED:20100211;REEL/FRAME:23854/652</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20100113</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:CELSIS IN VITRO, INC.;US-ASSIGNMENT DATABASE UPDATED:20100325;REEL/FRAME:23854/652</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:CELSIS IN VITRO, INC.;REEL/FRAME:023854/0652</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">KBC BANK NV, UNITED KINGDOM</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 24, 2010</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CELSIS IN VITRO, INC.,MARYLAND</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:IN VITRO TECHNOLOGIES, INC.;US-ASSIGNMENT DATABASE UPDATED:20100211;REEL/FRAME:23832/814</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20070424</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:IN VITRO TECHNOLOGIES, INC.;US-ASSIGNMENT DATABASE UPDATED:20100325;REEL/FRAME:23832/814</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:IN VITRO TECHNOLOGIES, INC.;REEL/FRAME:023832/0814</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CELSIS IN VITRO, INC., MARYLAND</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 13, 2010</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CELSIS IN VITRO INC.,MARYLAND</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC;US-ASSIGNMENT DATABASE UPDATED:20100211;REEL/FRAME:23768/838</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20100113</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC;US-ASSIGNMENT DATABASE UPDATED:20100325;REEL/FRAME:23768/838</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC;REEL/FRAME:023768/0838</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CELSIS IN VITRO INC., MARYLAND</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 22, 2009</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CELSIS IN VITRO, INC., MARYLAND</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:IN VITRO TECHNOLOGIES, INC.;REEL/FRAME:023686/0299</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20091222</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 6, 2007</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BARCLAYS BANK PLC, UNITED KINGDOM</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:IN VITRO TECHNOLOGIES, INC.;REEL/FRAME:019122/0755</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060720</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 21, 2005</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">IN VITRO TECHNOLOGIES, INC., MARYLAND</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DRYDEN, DANIEL;HARDY, JAMES;REEL/FRAME:016981/0661</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20050419</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U14gSLHwX2AggQofVYgF6Fg3cRbYw\u0026id=-FvnBQABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U1CGBS4Djk6TjjsX7hKGklLqli5eA\u0026id=-FvnBQABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U3mRs_USAlLlbmVggRmH7Pwtz7pGw","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Hepatocyte_cryopreservation_density_grad.pdf?id=-FvnBQABERAJ\u0026output=pdf\u0026sig=ACfU3U29tbtC6qOMuKV6bhjuKvGENcMq4A"},"sample_url":"http://www.google.com/patents/reader?id=-FvnBQABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>